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Zusammenfassung 
Thyronamine (TAM) sind eine neue Molekülklasse, die endokrinologische und metabolische 
Prozesse miteinander vereinen. Der biologisch aktive Metabolit 3-Iod-L-Thyronamin (3-
T1AM) wird durch eine kombinierte Deiodierung und Decarboxylierung von Schilddrüsenhor-
monen (TH) gebildet. 3-T1AM ist als 'kühlender' Metabolit in seiner pharmakologischen Wir-
kungsweise das Gegenstück zum klassischen 'thermogenen' TH 3,3',5-Triiod-L-Thyronin 
(T3). Existierende Methoden zum Nachweis und zur Quantifizierung von 3-T1AM im mensch-
lichen Serum sind immer noch umstritten. Auch die an der Biosynthese vermutlich beteiligte 
TH-Decarboxylase konnte noch nicht identifiziert werden.  
Für die gleichzeitige Identifizierung und Quantifizierung von TH und TAM Profilen in biologi-
schen Proben wurde die Flüssigchromatographie-Tandem-Massenspektrometrie (LC-
MS/MS) verwendet. Gleichzeitig wurden mehrere präanalytische Methoden für eine vollstän-
dige Extraktion von 3-T1AM aus humanem Serum getestet. In der bisherigen präanalytischen 
Aufarbeitung humaner Proben liefern weder Flüssig-Flüssig- noch Festphasenextraktionen 
reproduzierbare Ergebnisse des 3-T1AM-Gehalts in humanem Serum. Mit der Entwicklung 
eines schnellen und spezifischen Extraktionsverfahrens und nachfolgender Detektion mittels 
LC-MS/MS gelang der gleichzeitige Nachweis der häufigsten TH in einzelnen humanen Se-
rum-Proben, d.h. 3,3', 5,5'-Tetraiod-L-Thyronin (Thyroxin, T4), T3, 3,3`,5`-Triiod- L-Thyronin 
(rT3) und 3,5-Diiod-L-Thyronin (3,5-T2). Parallel dazu wurden monoklonale Antikörper (MAb) 
gegen 3-T1AM entwickelt und charakterisiert, auf deren Basis ein hoch sensitiver quantitati-
ver 3-T1AM MAb Chemilumineszenz-Immunoassay (CLIA) entstand. Ergebnisse aus klini-
schen Kollektiven zeigen, dass 3-T1AM in menschlichem Serum im nanomolaren Konzentra-
tionsbereich vorkommt und dass 3-T1AM bei Patienten außerhalb der Schilddrüse produziert 
wird. Jedoch konnte mittels LC-MS/MS auch endogenes 3-T1AM in murinen Schilddrüsen 
nachgewiesen werden. Viele Forscher gehen davon aus, dass die aromatische L-
Aminosäure Decarboxylase (AADC) die Synthese von TAM über Decarboxylierung von TH 
katalysiert. Diese Hypothese wurde durch Inkubation von rekombinanter humaner AADC mit 
mehreren TH unter vielen verschiedenen experimentellen Bedingungen getestet. In keinem 
der Experimente konnte funktionell aktive AADC die Decarboxylierung von TH katalysieren, 
so dass die ursprüngliche Hypothese widerlegt wurde. Diese In-vitro-Beobachtungen werden 
durch die Feststellung unterstützt, dass 3-T1AM auch in Plasma-Proben von Patienten mit 
AADC-Mangel detektiert wird.  
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Zusammenfassend ist die Bestimmung von 3-T1AM in humanem Serum mittels LC-MS/MS 
aufgrund der nicht reproduzierbaren präanalytischen Probenaufbereitung problematisch. In 
dieser Arbeit wird der erste MAb-basierte 3-T1AM assay vorgestellt, der 3-T1AM zuverlässig 
in humanem Serum quantifiziert. AADC, der erste Kandidat für die Decarboxylierung von TH, 
ist wahrscheinlich nicht an der Biosynthese von TAM beteiligt. TAM werden vermutlich mit 
Hilfe einer anderen, noch nicht bekannten, Decarboxylase gebildet.  
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Abstract 
Thyronamines (TAM) are a new class of molecules linking endocrinology and metabolism. 
Combined deiodination and decarboxylation of thyroid hormones (TH) generates a biologi-
cally active ‘cooling’ metabolite, 3-iodo-L-thyronamine (3-T1AM), whose pharmacological 
actions are opposite to those induced by the classical thermogenic TH 3,3`,5-triiodo-L-
thyronine (T3). It remains controversial, which methods are able or not to reliably detect 3-
T1AM in human serum, and the presumed TH decarboxylase is still elusive.  
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used for the simultane-
ous identification and quantification of TH and TAM profiles in biological samples. Several 
preanalytical methods were tested for complete extraction of 3-T1AM in human serum. Thus 
far, neither liquid-liquid nor solid-phase extraction methods allowed reproducible extraction of 
3-T1AM from human serum samples in the preanalytical sample workup. Nevertheless, a 
rapid and sensitive extraction procedure was developed for detection of the major TH, 
3,3`,5,5`-tetraiodo-L-thyronine (thyroxine, T4), T3, 3,3`,5`-triiodo-L-thyronine (rT3) and 3,5-
diiodo-L-thyronine (3,5-T2), by LC-MS/MS in a single human serum sample. In parallel, 
monoclonal antibodies (MAb) targeting 3-T1AM were developed and characterized, and a 
highly specific quantitative 3-T1AM MAb-based chemiluminescence immunoassay (CLIA) 
was developed. Studies in clinical cohorts provide evidence that 3-T1AM is present in human 
serum in the nM concentration range and that 3-T1AM is produced extrathyroidally; however, 
using LC-MS/MS, endogenous 3-T1AM was also found in murine thyroid glands. Many re-
searchers have reasoned that the aromatic L-amino acid decarboxylase (AADC) mediates 
TAM synthesis via decarboxylation of TH. This hypothesis was tested by incubating recom-
binant human AADC with several TH under extensively varied experimental conditions. In all 
tested conditions, functionally active AADC failed to catalyze the decarboxylation of TH, thus 
refuting the initial hypothesis. These in vitro observations are supported by the finding that 3-
T1AM is also present in plasma samples of patients with AADC deficiency.  
In summary, 3-T1AM detection in serum using LC-MS/MS encounters preanalytical problems. 
The first MAb-based 3-T1AM CLIA is presented, which reliably quantifies 3-T1AM in human 
serum. AADC, the first candidate enzyme for TH decarboxylation, is likely not involved in 
TAM biosynthesis. Hence, TAM are probably formed by another, yet unknown, decarboxy-
lase.  
 IV 
 
Keywords  
Thyronamines 
3-iodo-L-thyronamine 
Thyroxine 
Thyroid hormone metabolism 
Liquid chromatography tandem mass spectrometry 
Monoclonal antibody 
Chemiluminescent immunoassay 
Aromatic L-amino acid decarboxylase
 V 
 
 
 Introduction 
1 
 
1 Introduction 
1.1 The thyroid gland as an endocrine organ 
The thyroid gland is a richly vascularized organ and the largest endocrine gland in the human 
body. This butterfly-shaped organ consists of two elongated oval lobes lying on either side of 
the trachea. These lobes are connected near their poles by a thin isthmus crossing the tra-
chea ventrally (Figure 1A). Macroscopically, the lobes of the thyroid consist of numerous 
spherical follicles of varying size which represent the structural unit of the thyroid gland 
(Figure 1B). The follicles consist of a polarized epithelial monolayer of cuboidal thyrocytes 
and are filled with a homogeneous, slightly acidophilic colloid (Figure 1C). This protein-rich 
colloid contains a large amount of thyroglobulin (Tg), a 660 kDa glycoprotein rich in tyrosine 
residues that serve as the scaffold for thyroid hormone (TH) synthesis. The interfollicular 
space is filled with connective tissue and is highly vascularized. Additionally, the hormone 
calcitonin is produced in the parafollicular cells (c cells) of the thyroid which migrate into the 
thyroid gland during development and descend from the neural crest (Figure 1C). Upwards 
from the isthmus, a pyramidal lobe is also often present. A fibrous or muscular band fre-
quently connects the pyramidal lobe to the hyoid bone.  
The most outstanding specialty of the thyroid gland is its ability to concentrate a large 
amount of iodide for the synthesis of TH. The thyroid gland is the primary source of all iodine-
containing compounds or their precursors whereas peripheral tissues are the source of TH 
metabolites. The synthesis of TH occurs at the apical surface of the follicular cells and iodi-
nated TH-containing Tg is deposited and stored as the colloid. TH are the main endogenous 
iodine-containing compounds with established physiologic significance in vertebrates. 
 
 
Figure 1: The position of the thyroid gland and histological structures. 
Gross anatomy of a normal thyroid gland (A) and histological appearance of thyroid follicles (B+C). 
Figure 1A was adopted from (Nussey and Whitehead, 2001). 
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1.2 Thyroid hormones (TH) 
TH, found in all chordate animals, are tyrosine-based hormones produced by the thyroid 
gland and are critical factors of brain and somatic development in newborns and of metabolic 
activity in adults. They occur in two forms, the inactive pro-hormone 3,3’,5,5’-tetraiodo-L-
thyronine (thyroxine, T4) and the biologically active 3,3’,5-triiodo-L-thyronine (T3), differing in 
the number of bound iodine atoms. 
 
1.2.1 Biosynthesis of thyroid hormones 
TH biosynthesis, storage, and release are regulated via the hypothalamus-pituitary-thyroid 
(HPT) axis and stimulated by thyroid-stimulating hormone (TSH) and the TSH-releasing-
hormone (TRH) (Figure 2 A). The HPT axis allows central control of TH production and se-
cretion by the thyroid gland and thus of the TH concentration in the circulation. In this axis, 
the hypothalamus produces TRH that stimulates the TSH secretion by the anterior pituitary, 
which in turn stimulates TH production by TH producing follicles of the thyroid gland. Through 
a negative feedback loop inhibiting TRH and TSH, TH regulate their own production. 
 
Figure 2: Hypothalamus-pituitary-thyroid axis (A) and thyroid hormone biosynthesis (B).  
Dehal: dehalogenase, Dio: deiodinase, DIT: diiodo-tyrosyl-residue Duox: dual oxidase, MIT: 
monoiodo-tyrosyl residue, NIS: sodium/iodide symporter, Tg: thyroglobulin, TPO: thyroid peroxidase 
(modified from (Schomburg and Köhrle, 2008)). 
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The TSH-receptor (TSHR) is localized at the basolateral membrane of thyroidal follicular 
cells. As a member of the G-protein-coupled receptor family, it is able to trigger both the Gs 
as well as the Gq/G11 pathway, resulting in stimulation of cAMP/proteinkinase A and phos-
pholipase C (PLC) signaling cascades, respectively. The cAMP pathway activates growth 
regulation and differentiation as well as TH secretion. The PLC pathway activates H2O2 gen-
eration and iodination through the PLC-dependent 1,4,5-inositol-tris-phosphate (IP3) 
Ca2+/diacylglycerol (DAG) pathway (Ohye and Sugawara, 2010).  
A crucial step in TH biosynthesis is the iodination of selected tyrosine residues of Tg. There-
fore, two iodide transporters, the sodium/iodide symporter (NIS, SLC5A5) in the basolateral 
membrane (Dai, et al., 1996; Dohan, et al., 2003) and the anion exchanger pendrin 
(SLC26A4) in the apical membrane of epithelial thyroctes (Gillam, et al., 2004; Royaux, et al., 
2000) convey iodide to the colloid lumen (Figure 2B). NIS co-transports two sodium cations 
with one iodide anion against an electrochemical sodium gradient as driving force, leading to 
an exceptionally high iodide accumulation by thyroid follicles. To produce the sodium gradi-
ent, the required energy is provided by the ouabain-sensitive Na+/K+-ATPase. In the follicular 
lumen, iodination of Tg tyrosyl residues and covalent coupling of these tyrosyls, are per-
formed by the heme-containing enzyme thyroid peroxidase (TPO). The first step yields mon-
oiodotyrosine (MIT) and diiodotyrosine (DIT). Only selected properly spaced MIT and DIT in 
Tg participate in the second coupling reaction forming T4 and T3 (Taurog, et al., 1996). For 
this purpose, H2O2 is generated at the apical membrane by NADPH-dependent dual oxi-
dases (DUOX 1/2) (De Deken, et al., 2000; Ohye and Sugawara, 2010). Excess MIT and DIT 
are deiodinated by an iodotyrosine dehalogenase 1 (Dehal1) after their proteolytic liberation 
from Tg inside the thyrocytes and generated iodide is recycled (Gnidehou, et al., 2004). 
 
1.2.2 Serum transport and cellular uptake of thyroid hormones 
After iodination and coupling of tyrosyl residues, the hormone-containing Tg is stored in the 
colloid lumen until hormone liberation. For TH liberation, hormone-containing Tg or peptides 
are internalized into epithelial cells and degraded by cathepsins (Brix, et al., 2001; Friedrichs, 
et al., 2003). Thereby, TH are liberated and can subsequently be released into the blood 
stream by TH transporters, where they bind to carrier proteins secreted by the liver like al-
bumin, transthyretin (TTR) or thyroxine binding globulin (TBG). Only small amounts of TH 
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(3% of T4, 6% of T3) are bound to lipoproteins (very-low-density lipoprotein (VLDL), low-
density lipoprotein (LDL) and high-density lipoprotein (HDL)) (Benvenga, et al., 1988). How-
ever, the vast majority of secreted hormone consists of T4 with a concentration range be-
tween 70-150 nM versus 1-3 nM T3 in human serum. Thus, total serum T4 concentration is 
about 60-fold higher than total T3 (Yen, 2001). These differences are compensated by a re-
duced affinity of T3 to TH binding proteins. 0.03% of the circulating T4 is unbound whereas 
0.3% of total plasma T3 is unbound (Yen, 2001).  
The prevailing hypothesis states that free TH concentrations are relevant for TH action and 
are recognized by their target cells (Ekins, 1992; Mendel, et al., 1988). Opposed to the previ-
ous concept that the lipophilic but charged TH enter target cells by passive diffusion, it has 
been shown that TH require plasma membrane transport proteins. Although several putative 
TH transporters have been identified, only the monocarboxylate transporter (MCT8) 
(Friesema, et al., 2003), MCT10 (Friesema, et al., 2008), the L-type amino acid transporters 
(LAT 1/2) (Friesema, et al., 2001) and the organic anion-transporting polypeptide (OATP) 
(van der Deure, et al., 2008) displayed high specificity/affinity towards TH transport.  
 
1.2.3 Systemic and local effects of the active thyroid hormone T3 
Once TH has been transported into the cell, TH can bind to nuclear TH receptors (TR) and 
elicit biological responses. T3 actions are mediated by two T3 receptors, TR! and TR", which 
are located on different somatic chromosomes and act as hormone-inducible transcription 
factors. The different forms of TR are expressed widely in tissue- and developmental stage-
specific patterns. These TR bind T3 with high affinity and mediate TH regulated gene tran-
scription. The TR bind to defined TH responsive elements (TRE) on the DNA, thus changing 
the expression of target genes. Depending on the structure and sequence of the TRE, ligand 
dependent or ligand-independent activation or also repression can be observed (Yen, et al., 
2006). Most cell types express TR, and thus are TH responsive. The most important target 
tissues of TH are the central nervous system, white and brown adipose tissue, bone, skeletal 
muscle and cardiovascular system. In this way, TH influences metabolism, energy and oxy-
gen consumption, bone growth and development. It increases cardiac functions, supports 
formation and activity of adipose tissue, stimulates liver functions and promotes brain devel-
opment (Yen, 2001). Amphibian metamorphosis for example is an important example of TH 
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actions on development (Becker, et al., 1997). In homeothermic species, TH additionally ac-
quired a role in metabolic regulation including thermogenesis (Kim, 2008).  
Most of the biological effects of T3 are mediated by TR regulation of target gene transcription 
in the nucleus. However, this classical concept of genomic TH action has become more di-
verse including now also the rapid non-genomic actions of T3 and T4 (Davis and Davis, 
1996). Non-genomic actions are independent of ligand binding to nuclear TR and are initi-
ated outside the nucleus but may end in cellular actions that are nucleus-mediated. The ef-
fects can be classified into TR-dependent or TR-independent pathways. The TR-dependent 
pathway rely on the cytosolic presence of the classical TR which can functionally interact 
with other kinase-signaling (mitogen-activated protein kinase (MAPK), extracellular signal-
regulated kinase (ERK1/2), Src kinase, phosphatidyl-inositol 3-kinase (PI3K)) pathways (re-
viewed in (Davis and Davis, 1996)). The TR-independent effects are mediated by specific 
membrane receptors for TH unrelated to the classical TR. As receptor for both T4 and T3, the 
plasma membrane receptor on integrin !"#3 has been identified to mediate the stimulating 
effects of TH on cell growth, proliferation, and angiogenesis (Bergh, et al., 2005; Davis, et al., 
2006; Davis, et al., 2009). 
1.2.4 Metabolism of thyroid hormones 
The TH T4 is synthesized in and secreted from the thyroid gland. It is the main secretory 
product of the thyroid gland in all vertebrates (Engler and Burger, 1984). In humans it is as-
sumed, that only approximately 20% of circulating T3 originate directly from the thyroid 
(Laurberg, 1984), while the thyroidal secretion of the T3 isomer 3,3’,5’-triodo-L-thyronine (re-
verse T3, rT3) is insignificant (Chopra, 1976). 
The main metabolic pathway for the peripheral T4 activation is reductive monodeiodination, 
whereby a hydrogen atom is exchanged for an iodine atom. Three selenocysteine-containing 
selenoproteins known as iodothyronine deiodinases (DIO 1, 2, 3) have been identified to 
exert this function. They show distinct tissue distributions, physiological functions and cata-
lytic specificities (Figure 3) (Bianco and Kim, 2006; Gereben, et al., 2008; Köhrle, 2000; 
Köhrle, 2002; Köhrle, 2007). However, not only T4 but also T3 and rT3 are substrates of deio-
dination reactions yielding further interesting TH metabolites, namely diiodo-L-thyronines 
(3,5-T2, 3,3`-T2, 3`,5`-T2), monoiodo-L-thyronines (3-T1, 3`-T1), and L-thyronine (T0).  
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Figure 3: Regulation of T3 bioavailability by local deiodinase activity. 
Deiodinases remove iodide (red) from the phenolic “outer” or tyrosyl “inner” ring of iodothyronines. 
 
However, DIO do not deiodinate the iodinated tyrosines MIT and DIT (Solis, et al., 2004). 
The deiodination pathway is responsible for degrading >70% of the T4 secreted by the thy-
roid gland. The remaining T4 is metabolized by alternative pathways (Figure 4) (Chopra, et 
al., 1978). These pathways are based on side chain modifications, their oxidative cleavage at 
the diphenylether link or conjugation of the 4’-phenolic group with sulfate or glucuronic acid 
(Visser, 1994; Visser, 1996; Wu, et al., 2005).  
 
Figure 4: Pathways of thyroid hormone metabolism. 
TH metabolites are generated by conjugation, i.e. sulfation or glucuronidation, deiodination, ether link 
cleavage or side chain modifications, i.e. deamination or decarboxylation. Modified from (Wu, et al., 
2005). 
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Sulfation and glucuronidation are so-called phase II detoxication reactions aimed to increase 
the water-solubility of the TH to facilitate their biliary and/or urinary clearance (Visser, 1994). 
The levels of TH sulfate in plasma, bile and urine are normally very low because of the rapid 
degradation of these conjugates by DIO1. In contrast to the TH sulfates, TH glucuronides are 
efficiently excreted in the bile. However, after intestinal hydrolysis of the TH glucuronides by 
bacterial ß-glucuronidases, part of the liberated TH is reabsorbed and again biologically ac-
tive, constituting an enterohepatic cycle (Visser, 1994; Wu, et al., 2005). 
Furthermore, there are two variations of TH side chain modification, concerning either the 
amine- or carboxyl group. Side chain decarboxylation combined with deiodination of TH 
leads to the formation of a novel class of biological active metabolites called thyronamines 
(TAM) (Piehl, et al., 2011; Saba, et al., 2010; Scanlan, et al., 2004). These metabolites influ-
ence the physiological manifestations of TH actions by inducing effects opposite from those 
stimulated by T3 (Liggett, 2004; Piehl, et al., 2011). It has been shown that TAM are sub-
strates for DIO (Piehl, et al., 2008), sulfotransferases (SULT) (Pietsch, et al., 2007), mono-
amine oxidases (MAO) and semicarbazide-sensitive amine oxidase (SSAO) (Saba, et al., 
2010; Wood, et al., 2009). However, no decarboxylating enzyme (s) catalyzing the conver-
sion of TH to TAM have been identified so far.  
Oxidative deamination of TH generates iodoacetic acids (TAc), tetraiodothyroacetic acid (tet-
rac), triiodothyroacetic acid (triac) and diiodothyroacetic acid (diac) etc., which are habitually 
present at low levels in human serum (Crossley and Ramsden, 1979; Gavin, et al., 1980; 
Pittman, et al., 1980; Ramsden and Crossley, 1986). Even though oxidative deamination is 
described as inactivating pathway for monoamines, triac has significant thyromimetic activity. 
In vitro it is more potent than T3 for transcriptional regulation by TR"1 and TR"2 isoforms, 
while regulation by TR!1 is equivalent for both ligands (Messier and Langlois, 2000; Moreno, 
et al., 2008). Interestingly, the cephalochordate Branchiostoma floridae, a marine inverte-
brate living in warmer coastal areas expresses a TH receptor, which is activated by triac but 
not by T3 (Paris, et al., 2008). Moreover, a naturally occurring non-selenodeiodinase catalyz-
ing 5-deiodination of tetrac and triac has been identified. These findings support the hy-
pothesis that triac is a primordial bioactive TH (Klootwijk, et al., 2011). 
Ether link cleavage (ELC) is only a minor pathway of TH removal in normal individuals 
(Balsam, et al., 1983; Kubota, et al., 1985; Wu, et al., 2005). This peroxidase-mediated reac-
tion leads to the formation of DIT from the amino acid site of the molecule (Balsam, et al., 
 Introduction 
8 
 
1983). The liberated iodine is in an oxidized state, allowing it to bind to proteins, resulting in 
the formation of iodoproteins (Wynn and Gibbs, 1964). Nevertheless, TH breakdown by ECL 
may support mechanisms for bactericidal activity during severe infections, since in patients 
with sepsis circulating DIT levels are elevated (Meinhold, et al., 1981; Meinhold, et al., 1988).  
1.2.5 Analytics of thyroid hormones 
Clinical diagnosis of TH parameters can supply key information on TH status. During the past 
decades, a lot of diagnostic procedures were presented for experimental and clinical TH 
analysis. These techniques include the development of simple but sensitive and specific 
methods for measuring TH. The first method for the quantification of TH was the determina-
tion of iodine content in serum. The concentration appeared to be closely correlated with the 
activity of the thyroid gland (Kydd, et al., 1950). Greater specificity and less interference from 
non-hormonal iodine-containing compounds were achieved with the development of the bu-
tanol-extractable iodine by column technique, which measures the total organic or hormonal 
iodine (Man, et al., 1954; Man, et al., 1951).  
All established chemical and chromatographic methods for serum TH measurement have 
been replaced by poly-and monoclonal antibody-based immunoassays. The hybridoma tech-
nique by Köhler and Milstein offered the opportunity to produce highly specific monoclonal 
antibodies (MAb). In 1974, they established the hybridoma technique for the production of 
MAb in cell culture. This method allowed the unlimited production of MAb with predetermined 
specificity and represents one of the most important inventions in biomedical research during 
the 1970s. MAb have opened up completely new fields for applied research and allow pre-
cise diagnosis of diseases. The principal features of the hybridoma technology are shown in 
Figure 5. 
In 1959, Yalow invented what is still one of the most significant methods of endocrine analy-
sis: the "radioimmunoassay" (RIA). In 1977 she received the Nobel Prize in Physiology or 
Medicine, together with Guillemin and Schally who identified hypothalamic releasing hor-
mones such as TRH. The first developed immunoassays for TH also used radioisotopic la-
belings (Brown, et al., 1970; Ekins, 1970; Ekins, et al., 1970).  
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Figure 5: Principal steps in the production of monoclonal antibodies. 
Spleen cells are prepared from mice, which have been immunized with a selected antigen. These cells 
are fused with myeloma cells maintained in culture. The product of this fusion is referred to as a hybri-
doma. By use of a sensitive detection method the hybridomas which produce the specific antibodies 
are identified and cloned. A particular hybridoma cell can subsequently be used for unlimited produc-
tion of a highly specific MAb which can be purified from cell culture supernatant. 
 
Later non-radioisotopic labels, such as enzymes (e.g. alkaline phosphatase, horseradish 
peroxidase (HRP)) and chemiluminescent molecules (e.g. acridinium esters and luminol) 
substituted the RIA methods to avoid radioactive exposure and expensive waste manage-
ment (Hata, et al., 1985; Miyai, et al., 1980; Schall, et al., 1978). However, significant biases 
for immunoassays have been reported due to either endogenous factors (e.g., abnormal 
binding proteins, dialyzable protein binding competitors, heterophilic antibodies, autoantibod-
ies) or in vitro factors (free fatty acids, bilirubin, immunoglobulins, assay antibodies, ana-
logues, intrinsic dilution) (Yue, et al., 2008). Due to their hydrophobic structure, TH exhibit 
very strong protein binding. Specific antibodies but also organic solvents used in the preana-
lytical sample workup along chromatographic or immunological detection procedures disrupt 
these in vivo serum or tissue binding equilibria. Up to now, several independent assays using 
multiple sample aliquots were necessary to obtain this information for selected TH com-
pounds and metabolites, for which antibodies were available. Sufficiently high discriminative 
specificity and affinity are needed to detect the most abundant compounds in the samples of 
interest. The issue of “precise analytical determination” of exact free versus total TH concen-
trations in body fluids such as blood serum, cerebrospinal fluid, saliva or urine under normal 
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and pathophysiological conditions fuels an ongoing debate on the rapid and “cost effective 
estimation” of relevant TH levels for clinical diagnostics. 
Therefore, analytical methods using gas chromatography–mass spectrometry (GC–MS) and 
liquid chromatography tandem mass spectrometry (LC–MS/MS) have been developed to 
measure TH in human serum or plasma to expand the immunological detection methods 
(Gu, et al., 2007; Kunisue, et al., 2010; Lembcke, et al., 2005; Soldin and Soldin, 2011; 
Soldin, et al., 2005; Yue, et al., 2008). LC-MS/MS has emerged as an innovative analytical 
technology applicable to numerous endocrine analyses (for review see (Krasnoselsky, et al., 
2008; Vogeser and Parhofer, 2007; Vogeser and Seger, 2010; Vogeser and Seger, 2012)). 
This technique identifies the analyte in a sample by the retention time and the mass-to-
charge ratio of parent and fragmentation ions (Figure 6). In a typical LC-MS/MS procedure, 
the sample is taken up by an autosampler and is injected into the stream of mobile phase 
using one or two pumps (Figure 6). The pumps move the mobile phase and the analyte 
through a HPLC-column (stationary phase) where the sample compounds are separated 
chromatographically before they are introduced to the ion source of the mass spectrometer 
(MS). In the MS instrument, the ion source converts the sample molecules into the gas 
phase forming charged ions. The ions are separated by electromagnetic fields according to 
their mass-to-charge ratio. The ions are detected, usually by a quantitative method and the 
ion signal is processed into mass spectra. In the selected reaction monitoring (SRM) mode, 
the first analyzer selects only for a specific single parent mass for MS/MS fragmentation and 
then the second analyzer monitors for a single user defined daughter ion. SRM allows for 
multiple user defined fragment ions. Quantification of analytes is achieved by determining the 
ratio of analyte to isotope labeled internal standard and calibration curves.  
 
Figure 6: Principle of the Liquid chromatography tandem mass spectrometry (LC-MS/MS). 
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LC-MS/MS assays are highly accurate and sensitive and they are specific for the analyte. 
This method has already been shown to be a precise tool for the measurement of serum 
testosterone, adrenal and gonadal steroids and 25-hydroxyvitamin D concentrations as well 
as TH (Adamec, et al., 2011; Jonklaas, et al., 2009; Kunisue, et al., 2011; Kunisue, et al., 
2010; Piehl, et al., 2008; Surowiec, et al., 2011; Thibeault, et al., 2012; Vogeser and 
Parhofer, 2007). Nowadays, LC-MS/MS is used in research laboratories as gold standard 
method in endocrine chemistry. However, clinical routine TH evaluation is still performed by 
immunoassays. In addition, routine laboratory chemistry methods do not include TH metabo-
lite (e.g. rT3 and 3,5-T2) measurements, since the concentration of these TH metabolites are 
in fact very low in human serum. The introduction of LC-MS/MS based techniques in the ana-
lytics of hormones, which circulate in 10-15 M (femtomolar) to 10-9M (nanomolar) concentra-
tion in various free and bound forms opened discussions and controversies on their ‘true 
concentrations’ in body fluids and tissues.  
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1.3 Thyronamines (TAM) 
Thyronamines (TAM) are a novel class of endogenous signaling molecules which can modu-
late metabolism. TAM were initially synthesized in the 1960-1990 by several groups studying 
TH metabolism (Cody, et al., 1984; Han, et al., 1987; Meyer and Hesch, 1983; Piehl, et al., 
2011; Scanlan, et al., 2004; Tomita and Lardy, 1956). Interest in TAM has significantly in-
creased, since they have been shown to be endogenous molecules in the human body ( 
Scanlan, et al., 2004; Scanlan, 2011). In terms of structure, TAM differ from TH by the ab-
sence of the amino acid carboxyl group. Similar to TH, there are nine TAM differing either by 
the number or by the position of iodine atoms (Figure 7).  
 
 
Figure 7: Structure and nomenclature of (A) thyroid hormones and (B) thyronamines. 
Adopted from Piehl & Hoefig, et al. (Piehl, et al., 2011). R: variable residue, I: iodine, H: hydrogen. 
 
Using LC-MS/MS, two representatives of nine possible TAM isomers, namely 3-Iodo-L-
thyronamine (3-T1AM) and the completely deiodinated product thyronamine L-T0AM, have 
recently been detected in vivo in serum and tissues of various species such as humans, 
C57Bl/6 mice, Long-Evans rats, Djungarian hamsters, and guinea pigs (Braulke, et al., 2008; 
Hoefig, et al., 2011; Saba, et al., 2010; Scanlan, et al., 2004). The endogenous presence of 
any other TAM in vivo has not yet been reported. 
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1.3.1 Systemic and local effects of thyronamines 
Combined deiodination and decarboxylation of TH generates the biologically active ‘cooling’ 
metabolite 3-T1AM. Animal studies showed that a single 3-T1AM treatment with a pharmacol-
ogical dose (50 mg/kg body weight) resulted in a rapid and drastic decrease in body tem-
perature (Scanlan, et al., 2004), drop in heart rate (Chiellini, et al., 2007), reduction in cardiac 
output (Chiellini, et al., 2007; Zucchi, et al., 2008) and an induction of behavioral inactivity in 
mice (Dhillo, et al., 2009; Scanlan, et al., 2004). These effects were shown to have poten-
tially neuroprotective benefits in case of ischemic injuries such as stroke (Doyle, et al., 2007; 
Lin, et al., 2011). Furthermore, a decreased respiratory quotient showed a shift from carbo-
hydrate to fat metabolism (Braulke, et al., 2008). Acute alterations in glucoregulatory hor-
mones and glucose metabolism (glucose#, insulin $, glucagon#) were observed. Decreased 
TSH and serum TH (T4 $, T3 $) indicated a perturbation of the normal feedback paradigm 
(Klieverik, et al., 2009; Regard, et al., 2007). Moreover, dose-dependent stimulation of food 
intake and neuropeptide Y release after intraperitoneal and intracerebroventricular 3-T1AM 
administration at lower doses has also been reported (Dhillo, et al., 2009). The pharmacol-
ogical effects of TAM are summarized in Table 1 and reviewed by Piehl & Hoefig, et al. 
(Piehl, et al., 2011). 
1.3.2 Serum transport and cellular uptake of thyronamines 
3-T1AM appears to prefer different serum proteins for binding as TH (Figure 8). Whereas TH 
strongly bind to TBG, TTR, albumin and only at minor extent to lipoproteins (Benvenga, et 
al., 1988), a high fraction of 3-T1AM (> 90%) is specifically non-covalently bound to apolipo-
protein B100 (apoB100) (Figure 8). The dissociation constant (KD) of 17 nM results in to a 
low free 3-T1AM concentration in serum (Roy, et al., 2012). The apolipoprotein occurs in 
plasma in two main isoforms, apoB100 and apoB48. In humans, apoB100 is expressed in 
the liver and is present on VLDL and LDL whereas apoB48 is expressed in the intestine and 
is present on chylomicrons and their remnants (Olofsson and Boren, 2005).  
The human circulating apoB100 concentration is 1.5 - 3.0 µM (77 - 153 mg/dL), depending 
on the lipid inventory which is regulated by nutrition, hormonal influences (estrogens, insulin, 
growth hormone), metabolic disorders (diabetes and obesity) and genetic background (e.g., 
cholesteryl ester storage disease, cholesterol ester transfer protein (CETP) deficiency, hypo- 
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Table 1: Summary of the pharmacological effects of thyronamines. 
 Experimental model Mechanism and/or interpretation Reference 
Central nervous effects 
Hypothermia C57Bl/6 mice, 
Djungarian hamsters 
Due to a decrease in metabolic rate (Braulke, et al., 2008; Doyle, et al., 2007; 
Scanlan, et al., 2004) 
Inhibition of monoamine transporters Transfected cell lines Hypothesized action as a relevant neu-
romodulator 
(Snead, et al., 2007) 
Cardiac effects 
Negative chronotropy*, 
Negative inotropy, 
C57Bl/6 mice, 
isolated rat hearts 
Due to effects on intracellular calcium 
homeostasis 
(Chiellini, et al., 2007; Ghelardoni, et al., 2009; 
Scanlan, et al., 2004; Zucchi, et al., 2008) 
Effects on plasma hormone concentrations 
Hyperglycemia, 
Hypoinsulinemia, 
Hyperglucagonemia 
Primary human and mur-
ine pancreatic !-cells,  
male Wistar rats, C57Bl/6 
and ROSA26PTX mice 
Hypothesized central action increasing 
the sympathetic tone on pancreatic is-
lets  
(Klieverik, et al., 2009; Regard, et al., 2007) 
Hypothalamus-pituitary-thyroid-axis: 
TSH ", T4 ", T3 " 
Male Wistar rats, 
C57Bl/6 mice 
Causing a state reminiscent of non-
thyroidal illness 
(Klieverik, et al., 2009; Manni, et al., 2012) 
Metabolic effects 
Metabolic rate ", 
RQ ", 
Lipid utilization #, 
Fat mass ", 
Ketonuria, 
mitochondrial O(2) consumption" 
C57Bl/6 mice, 
Djungarian hamsters 
 
 
 
Rat liver mitochondria 
Hypothesized action as a physiologically 
relevant modulator of metabolism: 
change in metabolic fuel utilisation from 
carbohydrates to mainly lipids 
(Braulke, et al., 2008; Venditti, et al., 2011) 
Legend: * Conflicting data have been reported for the cardiac effects of T0AM (Boissier, et al., 1973; Chiellini, et al., 2007; Cote, et al., 1974), " reduction; # in-
crease. 
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betalipoproteinemia, heterozygous familial hypercholesterolemia, familial combined hyperlip-
idemia, familial defective apoB100) (Beghin, et al., 2000). ApoB100 serves as a ligand for the 
LDL receptor (LDLR), which is mainly responsible for the removal of LDL from plasma. 
Hence, the physiological role of the strong binding of 3-T1AM to apoB100 may be to provide 
a mechanism for transportation and entry of 3-T1AM into target cells via LDLR mediated en-
docytosis (Roy, et al., 2012). The receptor mediated endocytosis involving apoB100 is a well-
established cellular uptake mechanism for small molecule lipids such as cholesterol and 
triglycerides (Benvenga, et al., 1988).  
 
Figure 8: Concept of thyroid hormone and thyronamine action within the cell. 
Thyroid hormones are bound in plasma to serum proteins like TBG, TTR and albumin. They enter a 
target cell via specific transporters, e.g. T3 uses the monocarboxylate transporter MCT8. Cytosolic T3 
exerts genomic effects via the nuclear TH receptor (TR). TH derivatives like 3-T1AM modulate the 
action of T3, e.g. counter-acting its systemic effects. 3-T1AM is bound to apolipoprotein B100 
(apoB100) and activates the G-protein coupled receptors (GPCRs) of the trace amine associated re-
ceptor 1 (TAAR 1) family followed by adenylylcyclase (AC) activation with subsequent rise of cAMP. 
Moreover, 3-T1AM is not transported into the cell via the TH transporters but maybe via yet unknown 
transporters (Ianculescu, et al., 2010; Ianculescu, et al., 2009). 3-T1AM itself inhibits TH transport and 
does not bind to the TH receptor. In the cell, 3-T1AM can be metabolized via deiodination (DIO), oxida-
tive deamination (MAO, SSAO) or conjugation with sulfate groups. 
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Systemic administration of 3-T1AM permits its passage through the blood–brain barrier, but it 
is unknown by which precise mechanism this occurs. Remarkably, 3-T1AM is not a substrate 
of TH transporters like MCT8 or MCT10 (Ianculescu, et al., 2010; Ianculescu, et al., 2009; 
Kinne, et al., 2010; Scanlan, et al., 2004). To identify putative 3-T1AM transporter(s), a sys-
tematic large scale screening analysis of the solute carrier (SLC) transporter family was per-
formed. No single specific TAM transporter was identified from this screen, however, sodium 
and chloride independent, pH dependent, TAM specific intracellular uptake, may involve mul-
tiple transporters (Figure 8) (Ianculescu, et al., 2010; Ianculescu, et al., 2009).  
 
1.3.3 Receptors of thyronamines 
The cellular transport mechanism could serve as a signal to terminate 3-T1AM action at its 
membrane receptors or provide a way of 3-T1AM recycling (Ianculescu, et al., 2009). Inside 
the cell, 3-T1AM may have other important but still undiscovered roles. The rapid onset of 
TAM effects led to their classification as non-genomic effects. The structural similarities of 
TAM with TH and biogenic amines suggested that TAM might signal either via nuclear TH 
receptors and/or cell membrane receptors of biogenic amines (Snead, et al., 2007). How-
ever, 3-T1AM cannot activate the classical slow acting TH receptors (Scanlan, et al., 2004). 
No other nuclear receptor activated by 3-T1AM has been identified up to now. So far, only 
trace-amine-associated receptor 1 (TAAR1) is activated by 3-T1AM and signals via adenylyl-
cyclase (AC) activation. However, a recent report rejects the hypothesis that TAAR1 medi-
ates the thermoregulatory response to 3-T1AM (Panas, et al., 2010). Surprisingly, the previ-
ously demonstrated hypothermic cryogenic response to 3-T1AM administration was 
maintained in TAAR1 knockout mice to a similar extent and with the same dose response at 
25 (~70 !mol) and 50 (~140 !mol) mg /kg body weight as in wildtype mice. 
Whether other members of the TAAR family or other plasma membrane receptors mediate 
this cryogenic 3-T1AM response, the therapeutic relevance for treatment of stroke, cardio-
vascular complications and intensive care medicine remains to be studied (Scanlan, 2011). A 
second receptor proposed to mediate the effects of 3-T1AM, was the "2A adrenergic receptor 
(Adra2A) which is an established G"i PCR expressed in many cell types including pancreatic 
#-cells and the heart (Regard, et al., 2007). 
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T3 increases heart rate, basal metabolic rate, and body temperature (Biggins and Koh, 2007; 
Flamant, et al., 2007). Hence, the effects of TAM are opposite to those of T3. This could be 
an indication that T3 and TAM act to maintain a homeostatic balance, with 3-T1AM serving as 
a quick brake to the more gradual stimulatory effects seen with T3 (Weatherman, 2007). TAM 
might fine-tune or even antagonize TH effects (Dratman, 1974; Liggett, 2004; Piehl, et al., 
2011; Scanlan, et al., 2004). These recent observations significantly expand the potential 
molecular and metabolic repertoire of TAM. Therefore, the biosynthesis, metabolism and 
action of 3-T1AM could be relevant factors in physiological and pathophysiological states like 
the low-T3-syndrome (Stathatos and Wartofsky, 2003), severe general and neurological dis-
eases or adaption to food and carbohydrate restriction. Extensively described variations of 
the T3 and rT3 serum levels cannot yet adequately explain the observed metabolic changes 
in relation to serum TH (Hesch, 1981; Kaptein, et al., 2009; Wartofsky and Burman, 1982).  
 
1.3.4 Biosynthesis of thyronamines 
TAM differ from TH only by a carboxylate group. Biosynthesis of TAM from TH therefore ap-
pears likely (Figure 9). If TAM were derivatives of TH, decarboxylation of the alanine side 
chain would be required for their biosynthesis. If the putative decarboxylating enzyme was 
converting only TH with higher iodine content, deiodination would be directly required to 
complete 3-T1AM and T0AM biosynthesis by removing at least one to four iodine atoms. 
However, the pathway of TAM biosynthesis is still elusive and controversially discussed 
(Ackermans, et al., 2010; Hoefig, et al., 2012; Saba, et al., 2010).  
 
Figure 9: Hypothetical biosynthesis of 3-T1AM from T4. 
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De novo biosynthesis would require partial oxidative iodination and ether-bond coupling of 
two tyrosyl rings resembling the biosynthesis of TH which occurs bound to their precursor 
protein Tg (Dunn and Dunn, 2001). Alternatively, de novo biosynthesis of 3-T1AM from T0AM 
would require iodination of T0AM. So far, both reactions have been described only within the 
thyroid gland, where they occur in the specialized compartment of the thyroidal follicle and 
involve TPO and DUOX (Ris-Stalpers, 2006). However, neither significant release of TH with 
lower iodination grade than T4 or T3 nor direct secretion of TAM from the thyroid gland has 
been reported, supporting the hypothesis of extrathyroidal TAM biosynthesis from TH. Fur-
ther support for this proposal comes from the ex vivo experiments where the exposure of 
H9c2 rat cardiomyoblasts to T3 but not to T4 led to very low but detectable 3-T1AM production 
(Saba, et al., 2010). Similarly, no 3-T1AM production could be observed in cultured primary 
rat thyrocytes and rat FTRL-5 thyrocytes offering T4 as substrate (Agretti, et al., 2011).  
A tentative biosynthetic pathway requires decarboxylation and several deiodination steps to 
convert e.g. T4 into 3-T1AM (Figure 10). Piehl, et al. have previously shown that the DIO are 
capable of reductively eliminating iodine from all positions in TAM (Piehl, et al., 2008). Nor-
mally, these three isozymes convert T4 into the active T3 (DIO1 and DIO2 (Köhrle, 2002; 
Watanabe, et al., 2006)) or into the inactive rT3 (DIO1 and DIO3). However, the TH decar-
boxylase, the sequence of reactions and locations of biosynthesis is still elusive at the mo-
ment (Wu, et al., 2005).  
 
Figure 10: Pathways suggested for thyronamine biosynthesis.  
Adopted from Piehl & Hoefig, et al. (Piehl, et al., 2011). Diagonal arrows: phenolic ring deiodination 
reactions catalyzed by DIO1 or DIO2 and tyrosyl ring deiodination reactions catalyzed by DIO1 or 
DIO3. Horizontal arrows: putative decarboxylation reactions which might represent the first step of 
TAM biosynthesis. Dashed lines: TAM which have been excluded as precursors of the biosynthesis of 
3-T1AM and T0AM. 
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Decarboxylation is a classical biochemical reaction in human physiology (Table 2). The list of 
enzymes of the Nomenclature committee of the International Union of Biochemistry and Mo-
lecular Biology (IUBMB) registered under EC 4.1.1 (carboxy-lyases) more than 90 known 
decarboxylase enzymes. For instance, the link between glycolysis and the citric acid cycle is 
the oxidative decarboxylation of pyruvate to form acetyl CoA. Moreover, amino acids are 
decarboxylated to primary amines also called biogenic amines. Several low-molecular-weight 
hormones are synthesized from amino acids. For instance, tyrosine is the precursor for the 
biosynthesis of dopamine, epinephrine, norepinephrine and as mentioned above TH. Many 
researchers have therefore reasoned that the aromatic L-amino acid decarboxylase medi-
ates TAM synthesis via decarboxylation of TH (Braulke, et al., 2008; Dratman, 1974; 
Klieverik, et al., 2009; Scanlan, 2009; Scanlan, et al., 2004). 
 
1.3.4.1 Aromatic L-amino acid Decarboxylase 
Aromatic L-amino acid decarboxylase (AADC, E.C. 4.1.1.28), also known as L-DOPA decar-
boxylase (DDC), is a ubiquitous enzyme and requires pyridoxal-5-phosphate (PLP, activated 
vitamin B6) as cofactor during the conversion of L-DOPA to dopamine or of 5-
hydroxytryptophan (5-HTP) to serotonin (Zhu and Juorio, 1995). However, the optimal condi-
tions of pH, temperature and substrate concentration are different for each substrate (Zhu 
and Juorio, 1995). In addition, AADC is also considered to be involved in the biosynthesis of 
trace amines such as tryptamine, tyramine and phenylethylamine (Dyck, et al., 1983; 
Saavedra, 1974). Since 1974, AADC has been proposed as a candidate for TH decarboxyla-
tion (Braulke, et al., 2008; Doyle, et al., 2007; Dratman, 1974; Klieverik, et al., 2009; Pietsch, 
et al., 2007; Scanlan, 2009; Scanlan, et al., 2004). This hypothesis is supported by the broad 
substrate specificity of AADC and the structural similarity of TAM to biogenic amines, also 
called monoamines (Figure 11) (Liggett, 2004).  
Other similarities between TAM and biogenic amines are: 1) 3-T1AM activates mouse TAAR1 
stably expressed in HEK293 cells, like other biogenic amines (Scanlan, et al., 2004). 2) 
SULT catalyze the sulfation of many endogenous compounds that include monoamine neu-
rotransmitters, such as dopamine, TH and 3-T1AM (Pietsch, et al., 2007). 3) 3-T1AM signifi-
cantly inhibited dopamine, norepinephrine, and serotonin transport indicating that these sub-
stances share the same transport systems (Snead, et al., 2007). 4) MAO and SSAO are 
promiscuous enzymes that prefer primary amine substrates, and can catalyze the  
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Table 2: Amino acids, their decarboxylated derivatives and biological function. 
Amino acid Biogenic amine Enzyme Biological function 
L-phenylalanine  phenylethylamine AADC  
L-tyrosine tyramine tyrosine DC  
L-tryptophane tryptamine AADC  
L-histidine histamine histidine DC 
L-DOPA dopamine AADC  
5-hydroxytryptophane serotonine AADC  
arginine agmatine arginine DC 
glutamate !- aminobutyric acid 
(GABA)  
L-glutamatic 
acid DC 
ornithine putrescine ornithine DC 
cysteinesulfinate hypotaurine CSAD 
serine ethanolamine serine DC 
threonine aminopropanol threonine DC 
asparate "-alanine aspartate DC 
cysteine cysteamine PDC 
lysine cadaverine lysine DC 
 
Legend: AADC: Aromatic L-amino acid decarboxylase; CSAD: cysteine sulfinic acid decarboxylase; DC: decarboxylase; PDC: Phosphopantothenoylcystein-
decarboxylase  
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oxidation of phenylethylamines and 3-T1AM (Wood, et al., 2009). 5) Cardiac 3-T1AM content 
averaged 6.6 pmol/g wet weight (Saba, et al., 2010), which is about two orders of magnitude 
lower than myocardial norepinephrine or acetylcholine content, but similar to epinephrine, 
dopamine, or adenosine content (Chiellini, et al., 2007). 
 
Figure 11: Pathway of dopamine and theoretical thyronamine biosynthesis.  
Aromatic L-amino acid Decarboxylase (AADC) catalyzes the conversion of L-DOPA to dopamine 
(right). 3-T1AM is structurally related to iodothyronines such as T4 (left). 
 
AADC deficiency (OMIM #608643) is a rare congenital error of neurotransmitter metabolism 
and one of the infantile movement disorders. In 1990, Hyland and Clayton reported the first 
patients with AADC deficiency (Hyland and Clayton, 1990; Hyland, et al., 1992). To date, 
less than 100 cases have been reported worldwide (Brun, et al., 2010; Korenke, et al., 1997; 
Lee, et al., 2009; Pons, et al., 2004; Swoboda, et al., 2003; Tay, et al., 2007) with a relatively 
high occurrence rate in Taiwan (Lee, et al., 2009). These patients are characterized by se-
vere neurometabolic disorders with developmental delay, prominent motor abnormalities, 
oculogyric crises and autonomic dysfunctions. In addition, they can develop endocrine symp-
toms, e.g. elevated prolactin, hypoglycaemia and growth hormone deficiency (Ide, et al., 
2009; Swoboda, et al., 1999; Swoboda, et al., 2003). These symptoms are caused by de-
fects in the ADDC gene (located in 7p12.1p12.3).  
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The diagnosis of AADC deficiency is made by analysis of neurotransmitters of cerebrospinal 
fluid (Brun, et al., 2010), the determination of AADC enzyme activity in plasma using both of 
its substrates, 5-HTP and L-DOPA (Hyland, et al., 1992; Verbeek, et al., 2007) and AADC 
gene mutation analysis (Brun, et al., 2010; Hyland, et al., 1992; Lee, et al., 2009). Nowadays, 
the preimplantation and prenatal genetic diagnosis of AADC deficiency with an amplification 
refractory mutation system-quantitative polymerase chain reaction is published to prevent 
births of AADC deficient patients (Kuo, et al., 2011). Available treatment options are limited 
(e.g. dopamine agonists, pyridoxine (vitamin B6) and MAO inhibitors) and have only marginal 
therapeutic effects while the prognosis is uncertain (Brun, et al., 2010; Pons, et al., 2004).  
In contrast, AADC becomes the rate-limiting step of dopamine synthesis in patients with 
Parkinson's disease treated with L-DOPA. Dopamine supplementation therapy was estab-
lished around 1970 and is still the gold standard for the pharmacotherapy of Parkinson's dis-
ease, an age-related movement disorder characterized by decreased levels of the neuro-
transmitter dopamine (Christine, et al., 2009). AADC activity is inhibited by carbidopa outside 
the blood brain barrier to inhibit the premature conversion of L-DOPA to dopamine (Nagatsua 
and Sawadab, 2009). After initial improvement with L-DOPA, many patients with Parkinson 
disease require higher doses for benefitial effects (Christine, et al., 2009) due to a severe 
loss of nigrostriatal nerve terminals leading to profound decreased activities of AADC. 
Hence, many researchers work on a AADC gene therapy using adeno-associated virus vec-
tor–mediated gene delivery of AADC to restore striatum-selective dopamine production 
(Christine, et al., 2009; Fan, et al., 2001; Li, et al., 2006; Muramatsu, et al., 2010; Ozawa, 
2007). 
 
1.3.5 Analytics of thyronamines 
3-T1AM has already been confirmed as an endogenous compound and was extracted from 
tissues and blood of several species like humans, mice, and rats (Hoefig, et al., 2011; Saba, 
et al., 2010; Scanlan, et al., 2004; Soldin, 2009). Using LC-MS/MS, the reported levels of 3-
T1AM and T0AM in serum ranged from 10-12 M (picomolar) to 10-9 M (nanomolar) due to dif-
ferent preanalytical extraction methods and device-dependent limits of detection (Table 3).  
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Table 3: Published methods for the quantification of thyronamines in serum. 
Publication Method Species 3-T1AM             T0AM 
(Scanlan, et al., 2004) Offline SPE + LC-MS/MS mouse n.q. n.q. 
(Braulke, et al., 2008) Offline SPE + LC-MS/MS hamster ~ 6 nM n.a. 
(Geraci, 2008) Offline SPE + LC-MS/MS human ~ 60 nM n.a. 
(Soldin, 2009) Online SPE + LC-MS/MS human ~ 0-92.6 pM n.a. 
(Saba, et al., 2010) Offline SPE + LC-MS/MS rat  ~ 0.3 nM ~0.04 pM 
(Ackermans, et al., 2010) Online SPE + LC-MS/MS rat/human n.d. n.d. 
(Galli, et al., 2012) Offline SPE + LC-MS/MS human ~ 0.2 nM n.a. 
(Manni, et al., 2012) Offline SPE + LC-MS/MS human ~ 0.2 nM n.a. 
Legend: SPE: solid phase extraction; n.a.: not analyzed; n.q.: not quantified, n.d.: not detected 
 
In 2008, Geraci, et al. reported at the American Thyroid Association (ATA) meeting the first 
endogenous 3-T1AM concentration in human tissues (higher concentrations in thyroid, skele-
tal muscle, adipose tissue and prostate ~60 nM, n=2-5) and serum (~60 nM, n=16) (Geraci, 
2008) using a solid phase extraction (SPE) and LC-MS/MS method described by DeBarber, 
et al. 2008 (Figure 12) (DeBarber, et al., 2008). 
 
Figure 12: Histogram of 3-T1AM levels in human serum and tissues.  
Modified from (Geraci, 2008). The concentration of 3-T1AM in human serum is about 60 nM [the grey 
bar]. Also high tissue concentrations in pmol/g were found in normal human thyroid tissues, suggest-
ing 3-T1AM may be synthesized by the thyroid gland, and in tissues previously shown to be affected 
by exogenous 3-T1AM administration or accumulated such as skeletal muscle and adipose tissues. 
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In 2009, Soldin, et al. described again at the ATA meeting a novel isotope dilution LC-MS/MS 
method for the simultaneous identification and quantification of 3-T1AM, T4, T3 and 3,3’-T2 in 
biological samples using a highly sensitive triple quadrupole mass spectrometer (API 5000™ 
LC/MS/MS System) (Soldin, 2009). However, human 3-T1AM concentrations measured with 
this method have not yet been published in a peer reviewed article. 
The presence of 3-T1AM in human and animal blood has been challenged by the publication 
of Ackermans, et al. (Ackermans, et al., 2010). Their online SPE extraction method combined 
with LC-MS/MS did not detect any endogenous 3-T1AM or T0AM in plasma from rats, nor in 
human plasma or thyroid tissue. They could only find 3-T1AM and T0AM in plasma and liver 
from rats treated with synthetic 3-T1AM and T0AM (Ackermans, et al., 2010). These negative 
findings raised doubts on the biosynthesis pathway and endogenous existence of 3-T1AM. 
Afterwards, 3-T1AM has again been confirmed as an endogenous molecule in rat blood and 
tissue (Saba, et al., 2010). The relationship between human 3-T1AM concentration, TH con-
centration and some common clinical chemistry variables was investigated in a recent study 
by Manni, et al. They measured an averaged 3-T1AM concentration of 0.219 ± 0.012 pmol/ml 
in healthy patients (n=22). The 3-T1AM concentration was significantly correlated to tT4, tT3, 
glycated hemoglobin, brain natriuretic peptide and !-glutamyl transpeptidase (Manni, et al., 
2012).  
Moreover, in a small cohort of patients, the group showed that 3-T1AM was significantly 
higher in diabetic (n=7) vs. non-diabetic patients (n=18) and significantly correlated with 
HbA1c levels suggesting a potential role of 3-T1AM in insulin resistance (Manni, et al., 2012). 
They did not find any significant difference in patients with cardiac dysfunction (Manni, et al., 
2012). 
The procedure of extracting 3-T1AM from human samples is analytically complex and time-
consuming. The sample capacity is limited and the access to a sensitive mass spectrometer 
is required. Up to the beginning of this thesis, no immunoassay as a classical TH method to 
measure 3-T1AM has been developed and published. 
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1.4 Aims of the study 
TAM have recently been described as endogenous signaling molecules which exhibit great 
structural similarity to TH, and biosynthesis from TH appears likely. While classically TH are 
determined via immunological methods, several LC-MS/MS methods have been reported for 
the detection of 3-T1AM in serum and tissues of various species. Nevertheless, controversies 
still exist about the appropriate method of detection as well as serum and tissue levels of 
endogenously present and exogenously administered 3-T1AM in body fluids and tissues. A 
tentative biosynthetic pathway of 3-T1AM formation requires decarboxylation and several 
deiodination steps to convert e.g. the pro-hormone T4 into the most potent TAM, 3-T1AM.  
 
The three central hypotheses of this project are:  
1) TAM are produced from TH by regulated decarboxylation and deiodination. 
2) Both classical immunoassay-based methods and novel LC-MS/MS analytics are suitable 
for direct quantification of TAM in body liquids and biological specimen or after preanalytical 
sample workup. 
3) The decarboxylation of TH to TAM is mediated by the non-selective enzyme AADC. 
 
Consequently the two main scientific goals for this work are:  
1) To establish the analytics to measure TAM and TH in different matrix compositions.  
2) To provide new insights into the biosynthesis and metabolism of TAM. 
 
As TH and their metabolites like TAM are powerful regulators of growth, development, meta-
bolic function, energy and structural metabolism of the body, the purpose of this project will 
be to gain more insight into the physiological role and biosynthesis of TAM. 
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2 Material and methods 
Suppliers of the chemicals and reagents (Table 4), TH related compounds (Table 5), labora-
tory equipment (Table 6), software (Table 7), and buffers (Table 8) used in this project can 
be found in Tables 4-8. 
Table 4: The chemicals and reagents used in this study were of highest purity available and 
obtained from the following companies  
Supplier 
Carl Roth (Karlsruhe, Germany)  
Sigma-Aldrich (Taufkirchen, Germany)  
Merck KGaA (Darmstadt, Germany)  
 
 r   ( r t t, r )  
VWR International (Hannover, Germany)  
 Boehringer (Mannheim, Germany)  
 Bio-Rad (Munich, Germany)  
 Fluka (Steinheim, Germany) 
 Roche Diagnostics GmbH (Penzberg, Germany) 
 Diagnostic Systems Laboratories (Webster, TX, USA) 
 Invitrogen GmbH (Karlsruhe, Germany) 
 PerkinElmer (Waltham, USA) 
 Serva Feinbiochemika (Heidelberg, Germany) 
 
 
Table 5: List of TH related compounds used in this study. 
Supplier and compound  
formula (Berlin, Germany)  
T0, 3-T1, 3’-T1, 3,3’-T2, 3,5-T2, 3’,5’-T2, T3, T3AM, rT3, rT3AM, T4, T4AM, Tetrac, Triac, Diac 
Thomas S. Scanlan, OHSU (Portland, USA) 
T0AM, 3-T1AM, d4-3-T1AM, 3’-T1AM, 3,3’-T2AM, 15N-3,5-T2, 3,5-T2AM, 3’-5’-T2AM, T1Ac, T0Ac 
Isoscience (King of Prussia, USA)  
13C6-T3, 13C6-rT3, 2H5-T4  
Table 6: List of equipment used for all analyses 
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Device Supplier 
Autoklav Varioklav Thermo Scientific (Waltham, USA) 
DELFIA Plate Shaker PerkinElmer (Rodgau-Jügesheim, Germany) 
Electrophorese chamber Bio-Rad Laboratories (Munich, Germany) 
Dissecting set FST Fine Science Tools GmbH (Heidelberg, Germany) 
Eppendorf concentrator 5301 Eppendorf (Hamburg, Germany) 
Magnetic stirrer Modell L32 A. Hartenstein (Würzburg, Germany) 
Centrifuge 5417R Eppendorf (Hamburg, Germany) 
Microdismembrator Modell U B. Braun Biotech (Melsungen, Germany) 
Microwave M501 Whirlpool (Schorndorf, Germany) 
iCyclerTM Thermal Cycler Bio-Rad Laboratories (Munich, Germany) 
Mithras LB 940 Luminometer Berthold Technologies (Bad Wildbad, Germany) 
Nanodrop ND-1000  PeqLab Biotechnologie (Erlangen, Germany) 
pH meter inoLab Benchtop WTW (Weilheim, Germany) 
Pipettes Eppendorf research 0,1-2,5 "l,  
0,5-10 "l, 10-100 "l, 100-1000 "l 
Eppendorf (Hamburg, Germany) 
Pipettor acu-jet pro A. Hartenstein (Würzburg, Germany) 
Hera cell incubator Heraeus (Hanau, Germany) 
Plate washer Hydroflex Tecan (Crailsheim, Germany) 
Vortex A. Hartenstein (Würzburg, Germany) 
Solid phase extraction station Agilent Technologies (Böblingen, Germany) 
 
Most of the used compounds only differ between the number and/ or position of an iodine 
atom or the deaminated/ decarboxylated side chain (Figure 13). 
The diiodo-L-thyronines, all internal standards and all TAM except for T4AM were dissolved 
in dimethyl sulfoxide (DMSO). T0, monoiodo-L-thyronines, triiodo-L-thyronines and T4AM 
were dissolved in DMSO-containing 100 "M hydrochloric acid. T4 was dissolved in DMSO-
containing 100 "M ammoniumhydoxide. All solutions were diluted with KH2PO4/K2HPO4-
buffer (100 mM, pH 7.4) to a final concentration of less than 1‰ DMSO in all experiments. L-
DOPA was always freshly prepared by dissolving it in KH2PO4/K2HPO4 buffer (100 mM, 
pH 7.4).  
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Figure 13: Chemical structures of 3-T1AM related compounds.  
All possible and available thyronamines, iodothyronines and thyroacetic acids are shown in compari-
son to the structure of 3-T1AM (grey box). 
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Table 7: List of software used in this work 
Software Supplier 
GraphPad Prism 5.01 GraphPad Software 
MicroWin 2000 Berthold Technologies  
MS Offce  Microsoft  
Multicalc program  PerkinElmer  
Analyst 1.5 AB SCIEX 
 
Table 8: List of buffers used in this work 
Buffer name Buffer composition 
Homogenization buffer 250 mM D(+) sucrose, 20 mM HEPES, 1 mM EDTA in H2O, pH 7.4, 
stored at 4°C 
Perfusion buffer 0.1 M Sodium potassium phosphate buffer, pH7.4 
1 x TAE buffer 40 mM tris-acetate, 1 mM EDTA in ddH2O, pH8.3, stored at RT 
6 x DNA loading buffer 0.25% (v/v) saturated, aqueous bromphenol blue solution, 30% (v/v) gly-
cerol in ddH2O, stored at RT 
Immunoassay buffer 50 mM Trizma®base, 154 mM NaCl, 20 "M DTPA, 0.01% Tween 40, 
0.05% NaN3, 0.05% bovine !-globulin and 0.5% BSA in ddH2O, filtration 
with 8 "m cellulose nitrate filter, pH 7.7 ,stored at 4°C 
Coating buffer 50 mM Na2HPO4 in ddH2O, pH 7.4, stored at room temperature (RT) 
Enhancement solution 100x Enhancement solution I 
100 mM thenoyltrifluoroacetone, 10 mM tri-n-octylphosphinoxide, 2% 
EtOH and 20% Triton®X-100 in ddH2O, stored at 4°C 
10x Enhancement solution II 
68 mM KHP and 6% acetic acid in ddH2O, stored at 4°C  
Working solution  
1% Enhancement solution I mixed with 10% Enhancement solution II, 
stored at RT, wrapped with aluminium foil 
PBST 4 PBS tablets were dissolved in 1L ddH2O and 0.01% Tween 40 were 
added, stored at 4°C 
AADC incubation buffer 100 mM KH2PO4/K2HPO4 buffer, pH 7.4, stored at RT 
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2.1 LC-MS/MS analysis 
LC-MS/MS analysis of TH, TAM and TAc in biological samples were performed using a Shi-
madzu ultrafast liquid chromatograph (UFLC) system consisting of a controller unit, two 
pumps including a degasser (Shimadzu Scientific Instruments, Columbia, MD, USA) and an 
autosampler (CTC Analytics AG, Zwingen, Switzerland). Data processing was performed 
using Analyst version 1.5. Software . 
The column oven and the autosampler were operated at 40°C and 10°C, respectively. Ana-
lytes were detected using a QTRAP®4000 triple-quadrupole tandem mass spectrometer (AB 
SCIEX, Darmstadt, Germany) equipped with a TurboIonSpray interface. Nitrogen served as 
nebulizer, curtain and collision gas. Because the analytes fall into different chemical classes, 
depending on ionizable groups including acids (TAc), bases (TAM), and zwitter ions (TH), it 
was necessary to develop two different methods. Although TH and TAM can be analyzed in 
the positive and negative (ESI) mode, the TAc were only detectable in the ESI negative 
mode. Since the highest sensitivity for TAM and TH was reached in the positive mode, a 
second negative ESI run was established to measure the TH, TAM and TAc in one sample.  
The detection was performed in the selected reaction monitoring (SRM) mode. The device-
specific mass spectrometric working parameters used to record the parent ion mass spectra 
and product ion tandem mass spectra were: TurboIonSpray voltage (IS): 5500 V, curtain gas 
(CUR): 30 psi, collision gas (CAD): 5 psi, nebulizer gas (Gas1): 60 psi, heater gas (Gas2): 50 
psi, entrance potential (EP): 10 V, source temperature: 400°C, dwell time: 50 ms. Chroma-
tographic separation was achieved using a Synergi Polar-RP 80-Å column (150 x 2 mm; 
Phenomenex, Aschaffenburg, Germany) and an analytical Guard Cartridge System (4.0 mm 
x 2.0 mm, Phenomenex, Aschaffenburg, Germany), using a gradient elution program at a 
flow rate of 300 µl/min. For HPLC separation, 0.6% acetic acid in 5% acetonitrile was used 
as the aqueous mobile phase (A), and 0.6% acetic acid in 95% acetonitrile was used as the 
organic mobile phase (B) (Figure 14). 
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Figure 14: Parameters of the gradient elution program used for the chromatographic separa-
tion of TH/TAM (A) and L-DOPA/dopamine (B).  
Mobile phase A: 0.6% acetic acid in 5% acetonitrile was used as aqueous phase, mobile phase B: 
0.6% acetic acid in 95% acetonitrile was used as the organic phase. The figures show the portion of 
each mobile phase over the running time [min] of each method. 
 
Analytes were diluted in 1% acetic acid in H2O/acetonitrile (50:50 (v/v)) to obtain a 10 µM 
working solutions. This working solution was directly injected into the mass spectrometer at a 
flow rate of 10 µl/min using a Hamilton syringe device (Hamilton, Darmstadt, Germany). 
MRM transitions to be monitored and compound-dependent LC-MS/MS parameters are 
summarized in Table 9. 
Table 9: Optimization of compound-specific mass spectrometric parameters. 
Compound (m/z)a Q1b (m/z) Q3c DPd CEe CXPf 
Positive ESI mode 
T0 274.1 257.0 
215.1 
81.0 
81.0 
17.0 
27.0 
48.0 
14.0 
T1 400.0 382.9 
354.0 
86.0 
86.0 
21.0 
25.0 
12.0 
10.0 
T2 525.8 479.8 
151.9 
101.0 
101.0 
29.0 
125.0 
14.0 
26.0 
T3 651.8 605.7 
479.0 
116.0 
116.0 
29.0 
51.0 
18.0 
24.0 
T4 777.7 731.6 
350.9 
50.0 
50.0 
33.0 
53.0 
22.0 
10.0 
T0AM 230.1 213.1 
109.1 
76.0 
76.0 
19.0 
35.0 
14.0 
18.0 
T1AM 356.0 339.0 
212.1 
91.0 
91.0 
19.0 
27.0 
10.0 
14.0 
T2AM 481.9 464.8 
338.0 
101.0 
101.0 
21.0 
25.0 
6.0 
10.0 
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Legend:a (m/z): mass to charge ratio; b (m/z) Q1: m/z of parent ion in first quadrupole; c (m/z) Q3: m/z 
of most intensive product ion in third quadrupole; d DP: declustering potential (V); e collision energy 
(V); f collision cell exit potential (V). 
 
T3AM 607.8 590.9 
210.1 
116.0 
116.0 
23.0 
61.0 
20.0 
16.0 
T4AM 733.7 716.6 
151.9 
126.0 
126.0 
29.0 
127.0 
22.0 
26.0 
DOPA 198.2 152.1 
107.0 
61.0 
61.0 
23.0 
37.0 
26.0 
18.0 
Dopamine 154.1 137.1 
91.1 
71.0 
71.0 
17.0 
35.0 
10.0 
6.0 
d4-3-T1AM 360.0 343.1 
216.1 
86.0 
86.0 
21.0 
29.0 
10.0 
34.0 
15N-3,5-T2 535.9 488.9 
362.1 
91.0 
91.0 
29.0 
43.0 
14.0 
10.0 
13C6-T3/  
13C6-rT3 
657.7 611.8 
203.1 
101.0 
101.0 
31.0 
103.0 
16.0 
18.0 
2H5-T4 782.7 731.6 
201.0 
111.0 
111.0 
37.0 
97.0 
20.0 
14.0 
Negative ESI mode 
T0 271.9 
 
107.8 
 
-80.0 -70.0 -5.0 
T1 397.8 
 
126.8 
 
-95.0 
 
-36.0 -7.0 
T2 521.8 126.8 -85.0 -40.0 -7.0 
T3 649.7 126.8 -110.0 -60.0 -5.0 
T4 775.7 
 
126.9 
 
-105.0 -90.0 
 
-5.0 
 T0AM 227.9 
 
107.9 
 
-90.0 
 
-30.0 
 
-5.0 
 T1AM 353.7 
 
126.9 
 
-80.0 
 
-26.0 
 
-7.0 
 T2AM 479.9 
 
126.9 
 
-75.0 
.0 
-30.0 
 
-5.0 
.0 T3AM 605.9 
 
126.9 
 
-105.0 
 
-58.0 
 
-5.0 
 T4AM 731.7 
 
731.7 
 
126.9 
 
-110.0 
 
-86.0 
 
-5.0 
 T0Ac 242.8 
 
126.7 
 
-50.0 
 
-22.0 
 
-13.0 
 
 
T1Ac 368.9 
 
126.7 
 
126.7 
 
-40.0 
 
-14.0 
 
-21.0 
 
 
Diac 494.7 126.7 -35.0 -26.0 -7.0 
 Triac 620.7 126.7 -15.0 -58.0 -5.0 
 Tetrac 746.5 126.8 -90.0 -54.0 -11.0 
 d4-3-T1AM 357.9 
 
126.9 
 
-90.0 
 
-26.0 
 
-7.0 
 13C6-rT3 655.8 126.8 
 
-90.0 
 
-90.0 
 
-7.0 
 13C6-T3 655.7 126.8 
 
-90.0 
 
-74.0 
 
-7.0 
 2H5-T4 780.7 126.8 
 
-95.0 
 
-88.0 
 
-7.0 
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2.2 Preanalytical extraction procedures 
2.2.1 Liquid-liquid extraction procedure 
Extraction of all TH and TAM from the same biological sample was performed using a liquid-
liquid extraction (LLE) procedure as described before (Piehl, et al., 2008). Assays were per-
formed on serum, tissue homogenates, cell culture incubation medium, and cell culture 
lysate. Approximately 0.1-0.3 g of the tissue was homogenized at 4°C in 0.2 ml of homogeni-
zation buffer using a dounce homogenisator (glass/glass). Briefly, enzymatic reactions were 
stopped by adding 0.1 volumes 100% acetic acid. Subsequently, internal standards were 
added to each vial. Acidified reaction mixtures were incubated at 37°C for 30 min. Proteins 
were precipitated by adding three volumes ice-cold acetone followed by an incubation at -
20°C for 15 min. After centrifugation at 14.000 x g and 4°C for 5 min, supernatants were 
transferred into new Eppendorf tubes, acidified with 0.002 volumes 30% HCl, washed twice 
with 1 volume cyclohexane and then subjected to three subsequent extractions with 1.5 vol-
umes ethyl acetate. Organic layers were combined and evaporated to dryness at 45°C. 
Residues were redissolved in 30 µl 1% acetic acid in H2O/acetonitrile (90:10 (v/v)) and stored 
at -20°C until analysis by LC-MS/MS.  
 
2.2.2 Urea-solid phase extraction procedure 
Extraction of 3-T1AM from serum was performed using a modified SPE procedure as de-
scribed before (DeBarber, et al., 2008). Serum samples were spiked with IS. Three volumes 
8 M urea were added for 30 min at 80°C to dissociate 3-T1AM from binding proteins. Proteins 
were precipitated by addition of two volumes acetone, pH 4 (acidified with concentrated HCl). 
The samples were vortexed for 30 s and centrifuged at 14.000 x g for 5 min. The supernatant 
was removed and the samples were evaporated to dryness at 45°C. Residues were dis-
solved in 2 mL 100 mM phosphate buffer, pH 6, for loading onto 130 mg/3 mL cation-
exchange SPE cartridges. The cartridges were preconditioned under positive pressure with 
air using 2 ml methanol (2 mL), de-ionized water (2 mL) and phosphate buffer (1.5 mL). 
Samples were loaded onto the column under gravity and were sequentially washed with wa-
ter (2 mL). 3-T1AM was eluted with 2% (v/v) ammonium hydroxide in methanol (2 mL, then 
0.5 mL twice). The solvent was removed by evaporation and reconstituted in 30 "L 1% acetic 
acid in H2O/acetonitrile (90:10 (v/v)) and stored at -20°C until analysis by LC-MS/MS.  
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2.2.3 Solid phase extraction procedure 
The SPE procedure using HybridSPE® cartridge from Sigma Aldrich (Taufkirchen, Germany) 
was done according to the manufactures instructions. The technology utilizes a proprietary 
zirconia-coated particle, and exhibits a selective affinity towards phospholipids while remain-
ing non-selective towards a range of basic, neutral and acidic compounds. Therefore, 200 "l 
human serum was spiked with IS and deproteinized by a precipitating agent consisting of 1% 
formic acid in acetonitrile (1:3 (v/v)). The samples were vortexed for 3 min and centrifuged at 
3.000 x g for 5 min at RT. Precipitated protein was removed and the supernatant was trans-
ferred to a HybridSPE® cartridge. After applying vacuum, the resulting eluent was concen-
trated in an Eppendorf concentrator, reconstituted in 30 "L 1% acetic acid in H2O/acetonitrile 
(90:10 (v/v)) and stored at -20°C prior to LC-MS/MS analysis. 
 
2.3 Cell culture experiments 
2.3.1 Cell culture 
The rat thyroid follicular cell line FRTL-5 was used as model systems to study cellular TH 
and TAM uptake. Cells were cultured in COON’s-F12 supplemented with 10% FCS, 1% 
Penicillin/Streptomycin, 6H-Supplement (10 ng/ml Glycyl-L-histidyl-L-lysin Acetate, 10 nM 
Hydrocortisone, 10 µg/ml bovine Insulin, 10 ng/ml Somatostatin, 5 µg/ml apo-Transferrin, 100 
µU/ml TSH.) and 100 nM Na2SeO3 to allow for optimal expression of DIO selenoproteins.  
Cells were propagated in an incubator at 37°C, 95% humidity and at 5% CO2 (now referred 
as standard conditions). Medium was exchanged at 3-day intervals and cells were passaged 
on a weekly basis, using a 1:3 splitting ratio. In order to prepare TH treatments, cells were 
counted using a haemocytometer and seeded at a concentration of 5 x 104 cells per 6-well 
and grown to 70% confluence. After 24 h, all medium was removed and cells were washed 
twice with PBS. Cells were stimulated with the indicated concentrations of various TH me-
tabolites in serum-free medium. 
2.3.2 RNA extraction and cDNA synthesis 
RNA extraction was performed using RNAEasy Mini Kit according to the manufacturer`s in-
structions. (Qiagen, Hilden, D). Finally, the RNA-pellet was dissolved in 30 µl HPLC H2O. For 
determination of RNA concentration and purity, the extinction of 1 µl RNA was measured at 
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260 nm using the UV/Vis spectralphotometer Nanodrop ND-1000. cDNA was subsequently 
synthesized from 500 ng RNA using iScript kit (Bio-Rad, Hercules, USA) according to the 
manufacturer`s instructions. Incubations were performed in a thermal cycler. 
2.3.3 Polymerase chain reaction (PCR) 
In preliminary experiments, annealing temperatures between 58°C and 62°C were tested for 
each gene in order to optimize the sensitivity, specificity and efficiency of the reactions. The 
best conditions for the PCR were determined after a series of test-PCRs with a variation of 
distinct factors. The best conditions are displayed in Table 10. Annealing temperatures were 
chosen according to the used gene specific primers. 
 
Table 10: Optimized thermal cycler conditions for PCR analyses.  
Event Temperature [°C] Time [sec] Repetition 
Primery denaturation 94 60  
Denaturation 94 30  
Annealing 58 /60/ 62 30 40x 
Elongation 68 30  
Final elongation 68 150  
Storage 8 #  
For the PCR reaction, the KAPAHiFi-polymerase (KAPA Biosystems) was used. The PCR-
sample had a final volume of 25 µl (10 µl mastermix (containing buffer, 10 mM dNTPs and 
polymerase), 1 µl reverse primer (10 µM), 1 µl forward primer (10 µM), 2 µl template DNA, 
11 µl HPLC H2O). Primers sequences, fragment lengths and annealing temperatures are 
listed in Table 11.  
 
2.3.4 Gel electrophoresis of PCR products 
The sizes of the PCR products were estimated by the primer design and confirmed by hori-
zontal agarose gel electrophoresis. Therefore, 1.5% (w/v) Agarose was dissolved by boiling 
in 1 x TAE buffer. 5 µl ethidium bromide solution/100 ml gel were added, prior to the solidifi-
cation of the gel. For sample preparation, 10 µl PCR product and 3 µl 6 x DNA loading buffer 
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were adjusted to a final volume of 18 µl by adding 5 µl ddH2O. 15 µl of each sample were 
loaded onto the gel. To estimate the sizes of the PCR products, 5 µl molecular size marker 
(Gene RulerTM 1 kb DNA ladder plus (Fermentas, St. Leon-Rot, Germany), were also elec-
trophorized on each gel. Electrophoresis was performed for 90 min (100mV and 400mA run-
ning conditions) and using 1 x TAE buffer as running buffer.  
 
Table 11: List of rat gene-specific primer pairs used for PCR analyses including the respective 
nucleotide sequences, PCR fragment sizes and annealing temperature. 
Gene fw/ 
rev 
Nucleotide sequence  
(5’ ! 3’) 
Fragment 
[bp] 
Annealing 
[°C] 
fw TTAAGAACAACGTGGACATCAGG Dio1 
rev GGTTTACCCTTGTAGCAGATCCT 
197 60 
fw GCGACCTGACCACCTTTTACTAG Dio2 
rev GCAGCACATCGGTCCTCTTG 
191 60 
fw GGTGTCATCAGTGGGCCTCTA NIS 
rev CCCGTGTCCATTCCAGAACTG 
269 60 
fw GCCCAGTGGTAACGGAAGTA Pendrin (SLC26A4) 
rev CTGTGAGACCAGCACTTGGA 
217 60 
fw CCGGATATTGCAGAGACGAT Tg 
rev GGCAGCTTGGGATATATGGA 
128 60 
fw GCCCTTGAGAGAACCCTACC Duox1 
rev AGCCTGGTGTTTCCACACTC 
158 60 
fw CTGGACAGAGCCCTAGCAAC Duox2 
rev CCAGCTGTCCTCCAGAGAAG 
129 60 
fw TTGGATCTGGCATCACTGAACTT TPO 
rev ATCTTGTTGACCATGCTTCTGTTG 
149 60 
fw CCTCGCTATGGGCATGATCT MCT8 (SLC16A2) 
rev TGGTTGAAAGGCGAATGAGC 
202 62 
fw GACAGGGCGACAAATGAACT THR!1 
rev GGCCTGAAGGGAAATCTAGG 
239 58 
fw ATGCCTGGCAATACCTTGTC THR!2 
rev GCACTGGGCTACAGACATGA 
197 58 
fw GCTAGCCAAGAGGAAGCTGA THR"1 
rev GGGTGCTTGTCCAATGTCTT 
208 58 
fw TGAGGAGCAGTATCACAATCAG TAAR1 
rev ATTTGCACGATTAATTGACCTC 
181 58 
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2.4 Development of a monoclonal antibody-based immunoassay 
2.4.1 Conjugation of 3-T1AM to BSA and HRP 
To couple 3-T1AM to BSA, 10 mg/ml BSA (bovine serum albumin) and EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide) were dissolved in demineralized water. 4 mg/ml 3-T1AM 
was dissolved in DMSO and diluted 1:25 in 0.1 M MES (2-(N-morpholino)ethanesulfonic 
acid) buffer (pH 5.0). BSA, EDC as a coupling reagent and 3-T1AM were combined in a reac-
tion tube wrapped in aluminum foil, to form the 3-T1AM-BSA conjugate within 120 min of 
shaking at RT (Figure 15). The conjugate was dialyzed overnight at 4°C against PBS (pH 
7.4) using Slide-A-Lyzer Dialysis Cassettes (20K molecular-weight cutoff, Pierce Chemical 
Co., Rockford, USA), sterile filtered and stored frozen in aliquots at -20°C. 
 
 
Figure 15: Principle of the 3-T1AM conjugation to BSA to form the hapten for immunization.  
EDC was used for coupling 3-T1AM to the carrier protein BSA. EDC reacts first with a carboxyl group 
of BSA and forms an unstable amine-reactive intermediate that quickly reacts with the amino group of 
3-T1AM to form the amide bond of the 3-T1AM-BSA conjugate and release an urea by-product. 
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The same procedure was used to couple 3-T1AM to HRP (horse radish peroxidase) to form a 
labeled 3-T1AM-HRP complex for construction of the immunoassay. The protein concentra-
tion of the dialyzed 3-T1AM-HRP was measured to calculate the final 3-T1AM-HRP concen-
tration. The 3-T1AM-HRP conjugate was sterile filtered and stored in aliquots at 4°C. 
 
2.4.2 Immunization of mice with 3-T1AM-BSA conjugate 
Three two-month-old female BALB/c mice (Jackson Laboratory, Maine, USA) were immu-
nized with BSA-coupled 3-T1AM. The antigen was dissolved in TiterMax®Gold adjuvant ac-
cording to manufacturer’s recommendations (Sigma Aldrich, Taufkirchen, Germany).  
For priming, 50 "g of antigen was injected at four local points subcutaneously in each 
mouse. Immunized mice were boosted twice using 25 "g antigen in TiterMax®Gold. Blood 
samples were obtained from mice for measurement of serum antibodies. The anti-3-T1AM 
antibody titer within the serum of immunized mice was monitored using the same methods as 
used for the screening of hybridoma supernatants (see 2.4.9).The two last injections (25 "g 
antigen in PBS) were given intraperitoneally 3 and 2 days before harvesting the spleen from 
the mouse with highest antibody titer. Therefore, the immunized mouse was killed by cervical 
dislocation and the spleen was removed (Figure 16).  
 
 
Figure 16: Scheme of the mouse immunization protocol. 
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2.4.3 Preparation of lymphocyte cell suspension 
The mouse spleen will serve as a source of lymphocyte cells for fusion with mouse myeloma 
cells yielding hybridoma cells (Figure 5). The spleen was removed and placed into a tube 
containing 10 ml of cold, sterile DMEM (Dulbecco`s Motified Eagle`s Medium). The removed 
spleen was transferred into a petri dish with 10 ml DMEM without serum and minced to free 
the lymphocytes. The resuspended cells were counted using a haemocytometer to calculate 
the number of viable lymphocytes/ml. 
2.4.4 Preparation of a mouse myeloma cell line 
The mouse myeloma cell line PAI was used for hybridoma formation with spleen lympho-
cytes. PAI cells lost their ability to secret antibodies (non-secretor) and were originally iso-
lated from a B-lymphocyte tumor of a BALB /c mouse strain. Standard sterile cell culture 
techniques were used to prepare the PAI suspension culture for cell fusion. PAI cells were 
cultured in DMEM with 4.5 g glucose/l containing 4 mM L-glutamine, 100 U penicillin, 
100 "g/ml streptomycin, 1 "g/ml fungizon, 10% horse serum (HS) and 1 mM pyruvate (HT 
medium) in an incubator at 37°C, 95% humidity and at 10% CO2. Cells were fed every day 
and subcultured in the log phase under sterile conditions. Therefore, 10 ml of cell suspension 
was put into a fresh cell culture flask containing 10 ml of new, pre-warmed (37°C) medium. 
Cells were placed into an incubator under standard conditions. To determine the number of 
viable myeloma cells/ml the haemocytometer were used. 
2.4.5 Preparation of macrophage cells  
On the day of cell fusion, macrophage cells of an untreated BALB/c mouse were prepared as 
feeder cells for cell fusion. Feeder cells supply growth factors that promote growth of the hy-
bridoma cells. Hence, 5 ml sterile cold DMEM medium was injected into the peritoneal cavity 
of the mouse. The abdomen of the mouse was gently massaged and the macrophage cell 
suspension from the peritoneal cavity was drained. Macrophage cells were diluted in DMEM 
medium up to 10 ml, centrifuged for 5 min at 1,000 rpm and 4°C. After removing the super-
natant, cells were resuspended in 100 ml DMEM with 4.5 g glucose/l containing 4 mM L-
glutamine, 100 U penicillin, 100 "g/ml streptomycin, 1 "g/ml fungizon, 20% HS and 1 mM 
pyruvate (HAT medium). Ten 96-well plates were prepared with 4-5x103 feeder cells/ 100 "l 
HAT medium/ well and placed into an incubator under standard conditions. 
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2.4.6 Cell fusion using Polyethylene Glycol 1500 
Antibody-producing spleen cells have a limited life span. The fusion with immortal lymphatic 
myeloma cells results in an antibody-producing hybridoma with unlimited growth. The HAT 
medium allows only the fused cells to survive in culture. Fusion is accomplished by incubat-
ing freshly harvested spleen cells with myeloma cells in 50% Polyethylene Glycol (PEG) 
1500 (PEG 1500 (w/v) in 75 mM Hepes, pH 8.0, Roche Diagnostics GmbH, Penzberg, Ger-
many). PEG 1500 is a polyether substance that causes cell membranes to fuse. Single 
spleen cells from the immunized mouse are mixed with the previously prepared myeloma 
cells (2 x 107 cells) in 40 ml cold DMEM without serum to create a 5:1 ratio lympho-
cytes/myeloma cells. Cells were centrifuged for 5 min at 1,000 rpm and 4°C. After removing 
the supernatant, cells were resuspended in 40 ml fresh, cold DMEM and were centrifuged 
again for 5 min at 1,000 rpm and 4°C. The resulting supernatant was discarded very carefully 
and the remaining pellet was gently dispensed. Afterwards, 1 ml sterile pre-warmed 50% 
PEG 1500 solution was added to the cell mixture over the period of 1 min under softly agita-
tion. The cell suspension was placed into a 37°C warm water bath for 1 min, before 1 ml pre-
warmed DMEM was added over the period of 1 min under soft agitation. After another minute 
in the water bath, 19 ml pre-warmed DMEM was added over the period of 5 min and 30 ml 
over the period of 1 min under slow shaking. Following a further 5 min incubation period in 
the water bath, the cells were centrifuged for 5 min at 1,000 rpm and 20°C. The supernatant 
was discarded and the remaining pellet was gently dispensed in 50 ml pre-warmed HAT me-
dium. The first 10 ml were added over the period of 2 min followed by the remaining 40 ml 
within 5 min. The cell solution was distributed to the ten 96-well plates (50 "l/well) containing 
the feeder cells and placed in an incubator. The cells were fed with 50 "l fresh HAT medium 
after 4-5 days. After 7 days 100 "l conditioned medium was replaced by 100 "l of fresh HAT 
DMEM medium. Finally, cells were subcultured in HT DMEM medium every 4-5 days by re-
placing 100 "l conditioned medium with fresh medium. The supernatant from all hybrid cells 
was screened for production of the desired antibody (see 2.4.9). 
2.4.7 Expansion of the antibody-producing cells 
Positive clones were transferred into larger volumes of medium to ensure vigorous cell 
growth and cell division. Therefore, promising candidate cells in one 96-well plate were 
gradually transferred into bigger plates before the desired hybridoma cell clone is cloned by 
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“limiting dilution” (see 2.5.8 ) and expanded in a high density cell culture system (Mini-PERM, 
Heraeus (Hanau, Germany)). 
2.4.8 Cloning of hybridoma cells by “Limiting Dilution” 
Cloning by limiting dilution is a procedure for separating cells in cell culture. If one cell per 
well remains viable and proliferates, then an isolated clone will arise which produces only 
one specific antibody. A suspension of 4-5x103 feeder cells/ 100 "l HAT medium per 96-well 
plate was prepared. Approximately 0.2 ml of the lymphocyte cell suspension was placed into 
each well of a 96-well plate and incubated under standard conditions. 25 "l of the hybridoma 
cell solution from a 24-well plate were dispensed into all 12 wells of the first row of a 96-well 
plate. After softly mixing, 50 "l of each well were taken to the next 12 wells of the second 
row. This procedure was repeated until the last 12 well in the last row. The plates were incu-
bated at 37°C in 10% CO2 for 4-7 days without changing the medium. The supernatant from 
all wells that contain one hybridoma clone/well was screened for production of the desired 
antibody and the antibody specificity was tested by a screening assay (see 2.5.9). A second 
and third cloning by limiting dilution was performed to insure the production of a true clone. 
2.4.9 Screening of hybridoma supernatant and mouse serum 
96-well flat-bottom high binding microtiter plates (Maxisorp plates, Nunc, Roskilde, Denmark) 
were coated with 100 ng/100 "l 3-T1AM-KLH, 3-T1AM-BSA and BSA diluted in Na2HPO4 
buffer (pH 7.4) and incubated overnight at 4°C. After washing the plates 3 times with PBS 
containing 0.05% Tween-20 (PBST) using a Hydroflex® Strip plate washer, serum dilutions 
(1:2,000; 1:20,000; 1:200,000) from immunized mice or hybridoma supernatant (diluted 1:4 in 
assay buffer) were added to the plates (100 "L/ well) for 1 h at RT under agitation. Plates 
were washed again 3 times with PBST before a rabbit- anti-mouse antibody (10 ng/100 "l) 
diluted in assay buffer was added to the plates for 1 h at RT under agitation on a DELFIA ® 
Plate Shaker. After washing 3 times with PBST, 10 ng Europium labeled streptavidin per well 
in 100 "l diluted in assay buffer was added and incubated for 30 min at RT under agitation on 
a DELFIA ® Plate Shaker. After washing the plates 6 times with PBST, 0.2 ml enhancement 
solution was added to each well and incubated for 10 min on a DELFIA® Plate Shaker. The 
fluorescence signal was then read by VICTOR3™ Multilabel Counter (PerkinElmer, 
Waltham, USA). Concentrations were automatically calculated according to a standard curve 
fitting by the Multicalc program. 
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2.4.10 Freezing and thawing hybridoma cells 
Freezing of hybridoma cells was done using cells growing in a 24-well plate. 1 ml of the cell 
solution was transferred into a 15 ml falcon tube and centrifuged for 5 min at 1,000 rpm and 
RT. The supernatant was transferred into a 2 ml Eppendorf tube and 5% NaN3 was added 
before the supernatants were stored at 4°C. The remaining pellet was gently dispensed in 
0.5 ml freezing medium (50% (v/v) HS, 40% DMEM, 10% DMSO). Aliquots of the cell solu-
tion were transferred into cryovials, slowly frozen and stored in liquid nitrogen. Thawing of 
hybridomas was done very quickly by placing the frozen aliquot into the 37°C pre-warmed 
water bath until the cells are thawed. Cells were pipetted out into a new flask containing HAT 
medium. To wash out the DMSO-containing freezing medium, cells were centrifuged for 
5 min at 1,000 rpm and RT before the cells were placed in fresh HAT medium. 
2.4.11 Isotyping and purification of MAb 
MAb were isotyped using a mouse MAb immunoPure Monoclonal Antibody Isotyping Kit 
(Pierce Chemical Co., Rockford, USA) according to the manufacturer’s recommendations. 
The MAb were purified on a rProtein A Sepharose column with different conditions according 
to the isotypes of MAb and dialyzed against PBS using Slide-A-Lyzer Dialysis Cassettes 
overnight at 4°C. The optical density of the MAb was measured to calculate the final MAb 
concentration. The MAb was sterile filtered and stored in aliquots at 4°C. 
2.4.12 3-T1AM chemiluminescent immunoassay for human serum  
White 96-well flat-bottom microtiter plates (Maxisorp plates, Nunc, Roskilde, Denmark) were 
coated overnight at 4°C with a rabbit-anti-mouse antibody (100 ng/0,1 ml per well). The 
plates were washed 3 times with PBST. 25 "l 3-T1AM standard samples (0-500 nM) diluted 
in T3/T4 deficient serum or 7% BSA-PBST, respectively, control sera and serum samples 
were pipetted in duplicate into wells together with 25 "l HRP-labeled 3-T1AM (10 ng) diluted 
in 0.5% BSA-PBST. 50 "l of MAb 9C5 (2 ng) diluted in 0.5% BSA-PBST was added before 
the plates were incubated at RT under agitation on a plate shaker for 90 min. After a final 
washing step (6 times with PBST), 0.1 ml luminol-based substrate solution was added to 
each well and incubated for 10 min on a plate shaker. The chemiluminescent signal was then 
analyzed by a multilabel counter and concentrations were automatically calculated according 
to the standard curve. 
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2.4.13 3-T1AM chemiluminescent immunoassay for murine serum  
White 96-well flat-bottom microtiter plates (Maxisorp plates, Nunc, Roskilde, Denmark) were 
coated overnight at 4°C with the MAb 9C5 (40 ng/0,1 ml per well). The plates were washed 3 
times with PBS before 150 "l Liquid plate sealer®/ well (Candor Bioscience, Wangen im All-
gäu, Germany) were added to the plate. After 1 h incubation, Liquid plate sealer® was dis-
carded and the plate was dried overnight at 37°C. Afterwards, 25 "l 3-T1AM standard sam-
ples (0-500 nM) diluted in 7% BSA-PBST and serum samples were pipetted in duplicate into 
the wells of the coated 96-well plate together with 75 "l HRP-labeled 3-T1AM (10 ng) diluted 
in 0,5% BSA-PBST. The plates were incubated at RT under agitation on a plate shaker for 
90 min. After a final washing step (6 times with PBST), 0.1 ml luminol-based substrate solu-
tion was added to each well and incubated for 10 min on a plate shaker. The chemilumines-
cent signal was then recorded by a multilabel counter and concentrations were calculated 
using the EXCEL software according to the standard curve. 
 
2.4.14 Immunoprecipitation of 3-T1AM 
For the Immunoprecipitation experiment, the MAb 9C5 was coupled to magnetic beads. 
Therefore, 100 "l (50%) Sepharose4Fast Flow (1 mg/ml) was incubated with the MAb 9C5 in 
a 1.5 ml tube. The beads were washed twice with 1 ml PBST. After centrifugation at 
6,000 rpm for 2 min, the supernatant was discarded carefully. 200 "l PBST were added to 
the beads and the beads were aliquoted in 2 x 100 "l in 1.5 ml Eppendorf tubes. 1 ml serum 
or 7% BSA-PBST were spiked with 100 nM 3-T1AM and 100 "l MAb beads were added to 
the tube. The tube was incubated for 3 h under rotation at RT and afterwards over night at 
4°C. Next day, the tube was again incubated for 1 h under rotation at RT. Afterwards, the 
samples were centrifuged at 6,000 rpm for 2 min and washed 3 times with PBST. The super-
natant was discarded carefully and 100 "l 0.1 M sodium acetic acid (pH 3) were added to the 
pellet. The samples were shaken for 2 min at RT and finally centrifuged at 6,000 rpm and RT 
for 2 min. The supernatants were evaporated to dryness using an Eppendorf concentrator 
and resuspended in 30 "l 1% acetic acid in H2O/acetonitrile (90:10 (v/v)) and stored at -20°C 
prior to LC-MS/MS analysis. 
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2.5 AADC experiments 
2.5.1 AADC expression and purification 
The expression and purification of human, recombinant AADC was done by Dr. Mariarita 
Bertoldi (University of Verona, Italy) and is published in Hoefig, et al. (Hoefig, et al., 2012). 
2.5.2 AADC reaction in vitro 
All assays were performed with purified, recombinant human AADC. Heat-inactivated AADC 
(boiled for 5 min at 95°C) was used as a negative control in all experiments. The incubation 
with the natural substrate, L-DOPA served as a positive control. 1 "M L-DOPA was incu-
bated with 0.5 "M AADC preparation in KH2PO4/K2HPO4-buffer (100 mM, pH 6.8) and 
0.6 mM PLP for 30 min at 37°C. Using the same incubation conditions, this experiment was 
repeated for all TH.  
Thereafter, the impact of different factors on the decarboxylation of rT3 by AADC was tested 
varying buffer pH, incubation time, and temperature. To investigate the impact of the incuba-
tion time, 0.5 "M AADC preparation was pre-incubated with PLP (0.6 mM) in 
KH2PO4/K2HPO4-buffer (100 mM, pH 7.2) for 0.5 h at 37 °C. After adding 100 nM rT3, the 
reaction mix was incubated at 37°C. Different samples were transferred to new tubes in 2h 
intervals from 0 h-18 h. To study the effect of the buffer pH, 100 mM KH2PO4/K2HPO4 (pH: 
5.0, 6.0, 6.8, 7.2, 7.6, 8.0 and 8.8), and 0.5 "M AADC preparation was pre-incubated with 
0.6 mM PLP for 0.5 h at 37°C. Afterwards, 100 nM rT3 was added to the reaction mix fol-
lowed by an incubation for 30 min at 37°C. To study the impact of the incubation tempera-
ture, buffer containing 100 mM KH2PO4/K2HPO4 (pH 6.8) was used and the incubation tem-
perature was varied between 35°C and 43°C for 30 min. 
2.5.3 Extraction of TH and TAM analytes from AADC preparation 
Enzymatic reactions were stopped by heating the samples for 5 min up to 95°C. After cooling 
down, proteins were precipitated by adding 0.1 volume 100% trichloric acid and removed by 
centrifugation at 14,000 rpm for 5 min at RT. Supernatants were transferred to new Eppen-
dorf tubes and concentrated by drying at 30°C using an Eppendorf concentrator. The resi-
dues were dissolved in 30 "l 1% acetic acid in H2O/acetonitrile (90:10 (v/v)) and stored at -
20°C until LC-MS/MS analysis. 
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2.6 Clinical samples 
As internal control samples, we used the commercially available standard serum Lypho-
check® as a positive control and T4/T3 deficient serum as a negative control.  
Serum from 13 healthy volunteers (nine females and four males) was used to validate the 
assay and to study the normal concentration range of 3-T1AM.  
Ten patients with pituitary insufficiency (seven female, three male patients, age 28-57 years, 
with complete anterior pituitary deficiency (panhypopituitarism) in all but two patients where 
the corticotropic axis was preserved) under full T4 replacement therapy and after six days of 
L-T4 withdrawal were studied. Furthermore, 105 thyroid cancer patients on TSH suppressive 
L-T4 therapy (80 female and 25 male patients, age 18-84 years, 77 with papillary, 21 with 
follicular, three with Hurthle cell and four with medullary thyroid carcinomas) were examined.  
Sera from both clinical cohorts were obtained from the Department of Endocrinology, Christie 
Hospital, Manchester United Kingdom (Prof. Dr. med. Georg Brabant). All patients provided 
their informed consent and studies were approved by the local Ethical Committee. 
Plasma from four patients with biochemically confirmed AADC deficiency were obtained from 
the Zentrum für Kinder- und Jugendmedizin der Universität Heidelberg (Professor Dr. med. 
Georg Hoffmann). The study was approved by the local Ethical Committee. 
2.7 Animal organs 
Organs from male, adult, euthyroid C57Bl/6 wild type mice were kindly provided by PD Dr. 
Ulrich Schweizer (Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin 
Berlin, Germany). 
2.8 Statistical analysis 
GraphPad Prism 5 software was used for all computations with tests indicated in the figure 
legends. Statistical significance was defined as p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). 
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3 Results 
3.1 LC-MS/MS Analysis of thyroid hormones and thyronamines 
As the nine possible TH metabolites differ only in the number and/or position of iodine atoms 
and cover a broad serum concentration range (10-12 M (pM) to 10-9 M (nM)), their distinction and 
quantification by immunological methods is cumbersome. 
Several publications for the measurements of TH in serum and tissue using LC-MS/MS exist, but 
only one publication by Piehl, et al. (Piehl, et al., 2008) describes the simultaneous detection of 
eight TH and TAM in one analytical run. Dr. Piehl established a sensitive and robust SRM- 
based LC-MS/MS method using the 3200® triple-quadrupole tandem mass spectrometer (AB 
SCIEX) at the Bundesinstitut für Risikobewertung (BfR). Thereby, both 3,3`-T2AM and 3`,5`-
T2AM as well as 3,3`-T2 and 3`,5`-T2 were separated sufficiently to permit an unequivocal quali-
tative identification of each analyte. However, only an incomplete baseline peak separation was 
achieved for some analytes by the chromatographic method developed.  
In this project, the LC-MS/MS analyses were performed using a Shimadzu UFLC system and a 
more sensitive QTRAP®4000 triple-quadrupole tandem mass spectrometer at the In-
terdisziplinäres Endokrinologisches Speziallabor (IESL) (Charité-Universiätsmedizin, Berlin). 
Therefore, the published LC-MS/MS method by Piehl, et al. for the simultaneous detection of TH 
and TAM (Piehl, et al., 2008) in a single sample needed to be optimized concerning both the 
HPLC and the MS/MS conditions. The HPLC running time was reduced from 30 min to 20 min 
without a loss of base line peak separation. The compound-specific and device-specific mass 
spectrometric parameters were optimized for the used method. To provide additional information 
and to correctly identify the individual analytes, a second MRM transition for all compounds (1st 
transition for quantification, 2nd transition for confirmation) was recorded (Table 9). Since the 
offline extraction recovery, the chromatographic retention time and the ESI ionization in the 
mass spectrometry differ between all TH and TAM, five important deuterated internal standards: 
d5-T4, 13C6-T3, 13C6-rT3, 15N-T2, d4-T1AM) were recorded to improve the accuracy of the TH and 
TAM quantification (Figure 17). Adding the correct deuterated IS to the sample containing the 
desired analyte should correct for any matrix effect. 
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Figure 17: Representative chromatograms (two transitions per compound, blue and red traces) of 
the QTRAP!4000 LC-MS/MS analysis of all deuterated internal standards (15N-T2 (A), 2H5-T4 (B), d4-
3-T1AM (C), 13C6-T3, 13C6-rT3 (D)). 
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A key issue in LC-MS/MS analysis is the preanalytical workup or extraction of samples if these 
cannot be directly applied on the HPLC separation system because of analytical reasons, con-
tamination or matrix interference. However, the preanalytical workup may also be of advantage if 
analytes are hereby enriched in the sample and/or contaminants removed, resulting in better 
signal to noise ratios. As TH and TAM concentrations in serum and biological samples span 
several orders of magnitude ranging from lower pM to higher nM concentrations, Piehl, et al. 
developed a LLE based method for the isolation of TH and TAM from mouse liver homogenates 
and cell culture extracts (Piehl, et al., 2008).  
 
3.1.1 Liquid-liquid extraction for isolation of TH and TAM from serum 
The published LLE procedure was tested for the isolation of TH and TAM from human serum. 
Figure 18 shows a representative chromatogram for the LLE and LC-MS/MS analysis of 200 "l 
human serum. The intensity of the T4 and T3 peaks were above the limit of quantification (LOQ), 
the other metabolites were below the limit of detection (LOD) (rT3) or completely absent (3,5-T2 
and 3-T1AM). The measurement of more than the classical TH, T4 and T3, was not achieved with 
this preanalytical extraction. However, exogenous 3-T1AM or other TH metabolites added in se-
rum are detectable confirming the accuracy of the LC-MS/MS measurement. 
 
Figure 18: Representative chromatograms (two transitions per molecule) for the liquid-liquid ex-
traction and QTRAP®4000 LC-MS/MS analysis of 200 "l human serum.  
T4 and T3 are above the LOQ and rT3 is below the LOD. 
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3.1.2 Isolation of TH and TAM from tissue samples 
As the published LLE procedure was also used for liver homogenates, further mouse tissues 
were analyzed. Three mice (C57Bl/6) were perfused with potassium phosphate buffer (pH 7.4) 
and most organs were extracted to determine endogenous TH and TAM profiles. In several per-
fused organs T4, T3, rT3, 3,5-T2, and 3-T1AM were detected. A qualitative overview of TH and 
TAM profiles in perfused mice organs is given in Table 12. In every tested organ T4, T3, 3,5-T2 
and 3-T1AM could be detected. However, rT3 was only detected in testis and the adrenal gland. 
 
Table 12: Qualitative overview of mouse organs containing TH metabolites. 
Organ T4 T3 rT3 3,5-T2 3-T1AM 
cortex xxx xxx  xxx xxx 
cerebellum xxx xxx  xxx xxx 
pituitary xxx xxx  xxx xxx 
hypothalamus xxx xxx  xxx xxx 
testis xxx xxx xxx xxx xxx 
duodenum xxx xxx  xxx xxx 
ileum xxx xxx  xxx xxx 
caecum xxx xxx  xxx xxx 
jejunum xxx xxx  xxx xxx 
stomach xxx xxx  xxx xxx 
kidney xxx xxx  x xx 
adrenal gland xxx xxx xxx xxx xxx 
Legend: The number of x indicates the number of animals in which the analyte was detected. 
 
In rodents, T4 accounts for approximately 50% of the TH secreted by the thyroid gland. Hence, 
3-T1AM could be a major product of T4 metabolism in the thyroid. Therefore, TH and TAM pro-
files were analyzed in mouse thyroids. T4, T3, 3,5-T2 and 3-T1AM were detected in mouse thy-
roids to be in the range of pmol/g wet weight (Figure 19). While 3,5-T2 was clearly identified as 
single peak (Figure 19C), baseline peak separation was not achieved for the two other T2 iso-
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mers, 3,3`-T2 and 3`,5`-T2, (Figure 19C) observed close to the LOD by the chromatographic 
method developed herein. 3-T1AM was measured in the same concentration range as T4 and T3 
in murine thyroid tissue. The peak intensity for rT3 was below the LOQ to exactly quantify rT3 
(Figure 19B) in the thyroid gland.  
 
Figure 19: Representative chromatograms (two transitions per compound) (A-D) of the 
QTRAP®4000 LC-MS/MS analysis and quantification (E) of perfused mouse thyroids.  
Endogenous T4 (A), T3 (B), 3,5-T2 (C) and 3-T1AM (D) were detected above the detection limit. The peak 
quantification of three perfused mice is shown in Fig. 4 E. 
 
3.1.3 Cellular uptake studies with thyroid hormones 
The uptake of TH and 3-T1AM into cells is a crucial issue to study the cellular action and conse-
quently to understand the physiological role of these messengers. Cellular entry of TH is medi-
ated by plasma membrane transporters which on the other hand do not transport TAM. Hence, 
cellular uptake of T3 and 3-T1AM was also studied using the LLE based LC-MS/MS assay. 
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3.1.3.1 T3 uptake in MCT8 transfected MDCK1 cells 
In a first step, the LC-MS/MS method was validated for the uptake of T3 in direct comparison 
with an established 125I-T3 uptake assay (Figure 20). The advantage of using the LC-MS/MS is 
that the uptake of unlabelled ligands into cells can be directly measured.  
 
 
Figure 20: Comparison of T3 uptake measurements based on 125I-T3 internalization or QTRAP®4000 
LC-MS/MS analysis.  
Cell associated radioactivity depending on substrate (T3) concentration (A). Lines represent fitted binding 
isotherms. All data points were determined in triplicate and the mean values and standard errors of the 
mean are indicated. The experiments were performed two times with similar results. Eadie-Hofstee plot 
based on data from A (B). KM values were not approximated from the plot, but were directly calculated 
from the raw data using GraphPad software. 
 Results 
52 
 
Therefore, MCT8-transfected Madin-Darby canine kidney 1 (MDCK1) cells were incubated for 
three minutes with T3 at concentrations ranging from 500 nM to 12 "M containing or not 125I-T3 
as tracer to study the cellular T3 uptake (the cell culture and radioactive uptake (125I-T3) part of 
the experiment was done by Dr. Anita Kinne and published in Kinne, et al., (Kinne, et al., 2010)). 
Only MCT8 as a known TH transporter transports exclusively TH and does not transport other 
substrates like amino acids. The KM values determined by both methods, 4.7 "M by 125I-T3 up-
take and 7.5 "M by LC-MS/MS (Figure 20), are within the range reported for rat Mct8, i.e. 4 "M 
using Xenopus oocytes (Friesema, et al., 2003). Hence, the established LC-MS/MS procedure is 
comparable with classical uptake methods. Subsequently, the MCT8-mediated uptake of the TH 
derivatives T3AM and triac was also investigated in MDCK1 cells using LC-MS/MS. Even at 
50 "M, both compounds were not transported by MCT8 (Figure 21) whereas T3 as a known sub-
strate is transported. Thus, the direct assay shows that MCT8 requires the intact L-amino acid 
side chain for substrate recognition. 
 
Figure 21: Uptake of T3, T3AM and triac by vector and MCT8 transfected MDCK1 cells.  
Data are representative of one out of at least two independent uptake experiments performed in triplicate 
and analysed with the QTRAP®4000 LC-MS/MS. Intracellular T3, T3AM, and Triac isolated from the cells 
after incubation with 10 "M in FCS-containing medium. 
 
3.1.3.2 T3 uptake in endogenously MCT8 expressing FRTL-5 cells 
The rat FRTL-5 cell line is well-studied and widely used in thyroid research. These cells are un-
able to synthesize and secrete T3 in vitro under monolayer culture conditions. However, many 
genes involved in TH biosynthesis, cellular uptake, transport (e.g. MCT8) and receptor-mediated 
signaling of T3 and 3-T1AM are expressed in FRTL-5 cells (Figure 22). 
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Figure 22: FRTL-5 gene expression concerning TH synthesis, transport and signalling.  
A PCR with cDNA from FRTL-5 cells and specific primer was performed. The amount of template cDNA 
was the same in all samples. This picture shows the result of a gel electrophoresis (1.5 %, TAE-buffer) 
after the PCR. The GeneRuler™ 1 kb Plus DNA ladder (Fermentas) was used for sizing and approximate 
quantification of the observed PCR fragments.  
 
To study the TH and TAM uptake in FRTL-5 thyrocytes, which endogenously express MCT8, 
cells were incubated with 100 nM (200 pmol) T3 and 3-T1AM, respectively, for 30 min to study 
the uptake and metabolism of T3 and 3-T1AM. Cells were harvested after 0, 5, 10, 15, 20 and 30 
min and cell homogenates were extracted using the LLE and analyzed using the LC-MS/MS 
(Figure 23). LC-MS/MS analysis of cell lysates after incubation with T3 or 3-T1AM showed the 
successful uptake of the substances into FRTL-5 cells within 30 min. A baseline of T3 properly 
resulting from the FCS-containing media at approximately 0.05 pmol was detected in the control 
experiment with PBS. The intracellular T3 concentration increased in a linear manner over time, 
reaching a final level of approximately 0.25 pmol. 
In contrast, the kinetics of 3-T1AM uptake were characterized by an initial, rapid increase of 
intracellular 3-T1AM during the first 10 min of incubation followed by a plateau phase at ap-
proximately 3 pmol, suggesting saturation, metabolism or export out of the cell (Figure 23). 
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Figure 23: Uptake of T3 and 3-T1AM into FRTL-5.  
Representative chromatograms (two transitions per compound) of the QTRAP®4000 LC-MS/MS analysis 
of T3 (upper panel) and 3-T1AM (lower panel) after 30 min on FRTL-5 cells. Intracellular T3 and 3-T1AM 
isolated from FRTL-5 cells after incubation with 100 nM (200pmol) T3 or 3-T1AM in FCS-containing me-
dium (B). 
 
 
3.1.4 Solid phase extraction using urea for isolation of TH and TAM 
Since the re-discovery of 3-T1AM in 2004 by Scanlan and co-workers, the extraction of TAM 
from serum is a great issue (Scanlan, et al., 2004). The first protocol used for the serum extrac-
tion was established in the Scanlan laboratory at the Oregon Health & Science University 
(OHSU, USA) and based on an urea solid phase extraction prior to LC-MS/MS analysis. The 
protocol was based on a total T3 extraction procedure using LC-MS/MS published by Tai, et al. 
(Tai, et al., 2002). 
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Using the original extraction protocol with our experimental setup using one MS/MS transition 
per molecule, it was possible to detect endogenous T0AM, 3-T1AM, T3, rT3 and T4 in 500 "l hu-
man serum (Figure 24). Although the sample volume was relatively high, peaks of 3,5-T2 and 
other TH were not detectable and signal intensities for T4,T3, and rT3 were rather low. However, 
the extraction of these compounds was not reproducible on a daily basis. In most cases, the 
detection of endogenous 3-T1AM and T0AM was not observed, while spiking experiments with 3-
T1AM succeeded. The comparison of the retention times of the endogenous 3-T1AM with the 
deuterated IS proved the accuracy of the peak determination. 
 
Figure 24: Representative chromatogram of the QTRAP®4000 LC-MS/MS analysis of T0AM (A), T3 
(B), 3-T1AM (C), and T4 (D) in 500 "l human serum.  
This chromatogram was recorded before the second transition for each compound was used in the LC-
MS/MS method. 
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All wash fractions of the SPE extraction were collected and analyzed to ensure that 3-T1AM is 
not washed out during the preanalytical sample workup. Since this was not the case, several 
modifications (temperature, reagents, pH, sample volume, sample species, sample matrix, SPE 
methods) of the protocol were tested and compared to the original protocol (Table 13) to reliably 
detect 3-T1AM and other TH (e.g. T4, T3, rT3, 3,5-T2) in serum.  
 
Table 13 : Variation of the original solid phase extraction protocol. 
Parameter Original protocol Changes 
Incubation temperature 80°C 42°C 
Protein binding interfering agent 8M urea guanidium hydrochloride, protease K 
pH range pH 4.0 -6.0  Variation from acetic to neutral to basic conditions 
Protein precipitating agent Acetone acetonitrile, phosphoric acid 
Sample volume 100 "l Up to 1,000 "l 
Sample species Human mouse, rat, Xenopus laevis 
Sample matrix Serum plasma, urine, saliva 
Sigma-Aldrich: HybridSPE 30mg/ml,  
                           HLB-SPE 30 mg/ml 
Waters:              Oasis MAX 3cc 
SPE columns Varian:  
Bond Elute  
certify 
Phenomenex:    Strata screen C 150mg/ 3ml,    
                           Strata-x-cw 334 60 mg/3ml,  
                           Strata-x-c 334 60 mg/3ml  
 
Most of the changes lead to an improved detection of T4 and T3, but 3-T1AM was not detected in 
any instance. Simultaneous TH and TAM based LC-MS/MS analytics seem to have problems 
with preanalytical workup and/ or sensitivity of the used LC-MS/MS. After one year of trying to 
measure the TAM and TH profile of one serum sample in one analytical run, it was decided to 
focus on separate methods for TH and TAM analysis. 
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During the SPE optimization process, several SPE columns and procedures were tested. A pat-
ent pending SPE technology using 1 ml HybridSPE® cartridge was found which is designed to 
retain phospholipids. A major cause of ion suppression and matrix effects when using electros-
pray techniques has been shown to be from endogenous phospholipids. Phospholipid concen-
trations are present in extremely high concentrations in biological matrices and can vary greatly 
between subject samples and experimental time points. Using this SPE column, the peak inten-
sities of T4 and T3 were above the LOQ using the QTRAP®4000 mass spectrometer (Figure 25 
right). However, peak intensities for rT3 and 3,5-T2 were mostly below the LOD. To elucidate if 
the absence of endogenous rT3 and 3,5-T2 in serum samples is due to the sensitivity of the LC-
MS/MS, the performance of two different tandem mass spectrometers (QTRAP®4000 and 5500 
from AB SCIEX) was compared (Figure 25). 
 
Figure 25: Representative chromatograms (compare different ordinates) of TH analysis using Hy-
brid SPE of the same human serum analysed with the QTRAP®4000 and with the most sensitive 
QTRAP®5500 LC-MS/MS system (Prof. Daniel, Molecular Nutrition Unit, TU Munich). 
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While the QTRAP®4000 only revealed endogenous T4 and T3, the more sensitive QTRAP®5500 
additionally detects rT3 and 3,5-T2 at concentrations allowing quantification in the same human 
serum which was extracted twice with the HybridSPE® procedure (Figure 25 left). Remarkably, 
a 4.5-fold increase in peak intensity was achieved in case of lower iodinated compounds like 
3,5-T2 (Figure 26). This is of high relevance as these metabolites also occur at much lower 
serum concentrations than T4 and T3 
 
Figure 26: Comparative analysis of signal intensities of 1"M TH standard solution analyzed with 
the QTRAP®4000 LC-MS/MS system and with the most sensitive QTRAP®5500 system using the 
identical HPLC separation column and LC chromatographic conditions. 
 
The comparison of the LC-MS/MS devices proofed that the SPE method is worthwhile to ana-
lyze several TH, namely T4, T3, rT3, and 3,5-T2, in 200 "l human serum. However, no endoge-
nous TAM could be detected using the HybridSPE® procedure and the QTRAP®5500 analysis, 
although spiking experiments with 3-T1AM for the generation of standard curves worked very 
well. The complete method validation is still ongoing and is not part of this thesis. 
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3.2 Development of a chemiluminescent immunoassay targeting 3-T1AM 
Up to now, several SPE based LC-MS/MS methods have been reported for the detection of 3-
T1AM in serum and tissues of various species, but no poly- or monoclonal Ab applicable for con-
struction of a TAM and especially a 3-T1AM immunoassay had been reported. 
 
3.2.1 Generation of a monoclonal antibody targeting 3-T1AM 
MAb targeting 3-T1AM producing cells were generated using the hybridoma technology first de-
scribed by Köhler and Milstein (Köhler and Milstein, 1975). It is well understood that the immune 
response can be stimulated by conjugating small molecules to larger, highly immunogenic car-
rier proteins. Hence, 3-T1AM was chemically coupled to bovine serum albumin (BSA; 67 kDa) for 
successful immunization. Three BALB/c mice were immunized by the injection of BSA-coupled 
3-T1AM to generate MAb targeting 3-T1AM (Figure 15). After three immunization injections, se-
rum Ab titer assays indicated that all three mice responded with high antibody titers and dis-
played high antibody avidity for 3-T1AM-BSA, particularly that from mouse number three. BSA 
itself as the hapten conjugation partner does not interfere with the assay (Figure 27).  
 
Figure 27: Proof of the specificity of the polyclonal antisera against 3-T1AM.  
Assay results with serum of three mice (A). 3-T1AM-BSA assay results with different serum dilutions (B). 
Mouse three showed highest antibody titer with 3-T1AM coupled to BSA and was used for the production 
of hybridomas. 
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More than thirty wells of hybridomas were identified to produce antibodies binding to 3-T1AM 
with high affinity. Eight MAb were examined for their cross-reactivity for T1, T3 and T4, and three 
out of those, termed 5C11, 10D1, and 9C5 with high affinity and specificity to 3-T1AM were cho-
sen for cloning, expansion and further characterization.  
MAb 9C5 showed less than 0.1% cross-reactivity with T4 and T3 and less than 1% with most of 
the other TH, TAM and TAc. Only 3,5-T2AM and 3-iodo-L-thyroacetic acid (T1Ac) which so far 
have not been detected in human serum or tissue by chromatographic or LC-MS/MS methods 
showed a cross-reactivity of 12,4% and 5,1%, respectively (Table 14). With respect to potential 
cross-reactivity of Ab for TH, the most important concern is their affinity and detection of the 
most abundant TH T4 and T3. Based on the average total T4 serum concentration of 100 nM, less 
than 0.1% cross-reactivity with our antibody to T4 would lead to a variation of less than 0.1 nM. 
These data clearly indicate that this particular MAb against 3-T1AM is highly specific. Normal 
concentrations of all 3-T1AM related compounds in serum are given in Table 14. The concentra-
tion of each substance is dependent upon the amount synthesized and secreted, their affinity for 
carrier serum proteins, distribution in tissues, rate of degradation, and clearance. 
 
Table 14: Cross-reactivity and serum concentrations of 3-T1AM -related molecules. 
 Cross-reactivity [%] Human serum  
concentration [nM] 
reference 
Iodothyronamines (TAM)  
T0AM < 0.1 n.q.  
3-T1AM 100 ~ 60 (Geraci, 2008), * 
3’-T1AM < 0.1 n.d.  
3,5-T2AM 12.4 n.d.  
3,3’-T2AM < 0.1 n.d.  
3’,5’-T2AM < 0.1 n.d.  
T3AM < 1 n.d.  
rT3AM < 1 n.d.  
T4AM < 0.1 n.d.  
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 Cross-reactivity [%] Human serum  
concentration [nM] 
reference 
Iodothyronines (TH)  
T0 < 0.1 n.q.  
3-T1 < 0.1 0.075 (Corcoran and Eastman, 1983) 
3’-T1 < 0.1 0.059 (Chopra and Sabatino, 2000) 
3,5-T2 < 1 0.055 (Chopra and Sabatino, 2000) 
3,3’-T2 < 1 0.058 (Chopra and Sabatino, 2000) 
3’,5’-T2 < 1 0.085 (Chopra and Sabatino, 2000) 
T3 < 0.1 2.1 (Chopra and Sabatino, 2000) 
rT3 < 0.1 0.62 (Chopra and Sabatino, 2000) 
T4 < 0.1 110 (Chopra and Sabatino, 2000) 
Iodoacetic acids (TAc)  
Tetrac < 0.1 7.2 (Chopra and Sabatino, 2000) 
Triac < 0.1 2.8 (Chopra and Sabatino, 2000) 
Diac < 1 n.d.  
T1Ac 5.3 n.d.  
Legend: n.d., not detected so far in human serum; n.q. not quantified so far in human serum, * this study 
 
3.2.2 Immunoprecipitation of serum using the MAb 9C5 
MAb cell clone 9C5 appeared highly specific for 3-T1AM as demonstrated in Table 14. Addition-
ally, an immunoprecipitation experiment followed by LC-MS/MS analysis was performed with 
MAb 9C5 to confirm the specificity already seen in the cross-reactivity experiment. The recovery 
of 100 nM 3-T1AM added to 7% BSA-PBST as TAM/TH deficient matrix was 82%. Immunopre-
cipitation with the MAb 9C5 and 5 human serum samples and subsequent analysis of extracted 
antigens bound to the precipitated MAb 9C5 showed again that the MAb specifically recognizes 
3-T1AM but not T4 or any other TH or TAM, respectively. A representative chromatogram for d4-
3-T1AM, 3-T1AM and T4 as the TH with the highest concentration in serum is shown in Figure 28.  
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Figure 28: Representative chromatogram of the QTRAP®4000 LC-MS/MS analysis of the extracts 
bound to the precipitated MAb 9C5 in the immunoprecipitation experiment.  
The chromatographic separation and detection of the IS d4-3-T1AM (A), 3-T1AM (B) and T4 (C) is shown. 
While the IS and the endogenous 3-T1AM is detectable, no T4 is in the extracted sample. 
 
3.2.3 Development of a chemiluminescent immunoassay 
MAb 9C5 was selected for construction of the 3-T1AM chemiluminescent immunoassay (CLIA) 
due to its high specificity and low cross-reactivity with other TAM. 
In the competitive assay procedure, HRP-labeled 3-T1AM competes with 3-T1AM in serum for 
binding to a limited amount of anti-3-T1AM MAb (Figure 29). In order to obtain the optimal assay 
conditions, all assay parameters and incubation times were optimized. 
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Figure 29: Schematic diagram of the developed 3-T1AM chemiluminescent immunoassay. 
 
To prepare a standard curve for quantifying 3-T1AM in human serum, 3-T1AM deficient human 
serum is needed. Therefore, several commercially available TH deficient sera were tested using 
the established immunoassay and 7% BSA-PBST as an artificial, 3-T1AM deficient serum matrix. 
Since the types and affinities of serum binding proteins differ between TH and TAM, TH deficient 
serum can still contain endogenous 3-T1AM. Four of five tested TH free sera contained 3-T1AM 
ranging from 25 to 55 nM 3-T1AM (Figure 30). 
Only the T3/T4 deficient serum from Sigma-Aldrich was below the lowest standard and therefore 
the matrix of choice lacking endogenous 3-T1AM. This serum is delipidated with fumed silica and 
dextran-coated charcoal treated to remove steroid hormones. Consequently, this T3/T4 and TAM 
deficient serum was used to construct the assay standard curve ranging from 0 to 500 nM 3-
T1AM. A typical standard curve using T3/T4 deficient serum or 7% BSA –PBST for the present 
assay is shown in Figure 31. 
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Figure 30: 3-T1AM analysis of five different TH deficient sera compared to normal control.  
Lyphocheck serum (Bio-Rad, München, Germany) served as positive control. Serum 1+ 2: two different 
charges of human, defibrinated, T3/T4- free serum (PAN BIOTECH GmbH, Aidenbach, Germany). Serum 
3: TSH, T3 & T4 depleted serum and 4: T3/T4 depleted processed serum (SCIPAC, Sittingbourne, United 
Kingdom). Serum 5: T3/T4 deficient serum (Sigma-Aldrich, Taufkirchen, Germany). 
 
The ratio of counts/ countsmax was used for calculation of the standard curve. Both standard 
curves are highly parallel suggesting comparable matrix effects. The linear concentration range 
of the 3-T1AM assay is from 10 to 200 nM. 
 
Figure 31: Standard curves for 3-T1AM using the CLIA.  
Increasing concentrations of non-labelled 3-T1AM were added to 7% BSA-PBST ($) or T3/T4 deficient 
serum (%) to displace binding of the 3-T1AM-HRP tracer. 
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3.2.4 Validation of the immunoassay 
Dilution linearity was assessed by assaying 3-T1AM standard samples after serial dilution with 
T3/T4-deficient serum. Measured concentrations were multiplied by the dilution factor and com-
pared with the original concentration. The results show a good agreement between the expected 
and the observed values in the steep part of the standard curve (Figure 31). The working range 
of the assay is estimated between 10-500 nM. The inter-assay precision of the assay was 18.5% 
and the intra-assay precision was 10.8%. 
Recovery of 3-T1AM measurement was tested by comparing the data of 5 sera in different com-
binations of equal volume mixtures of two sera each (Figure 32 left). Measured concentrations 
from each mixture of two sera were added up in order to obtain the theoretical value for the 
measurement of the equal volume mixtures. Results agreed with the theoretically expected 
arithmetic means for the corresponding samples and was <5% for all mixed samples. 
Furthermore, recovery of 3-T1AM spiked to serum in rising concentrations (0-50 nM) was studied 
(Figure 32 right). Mean recovery of the theoretical values to the measured data determined by 
the assay was < 5% for all spiked samples.  
 
Figure 32: 3-T1AM immunoassay validation.  
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In this recovery study, different combinations of mixtures of two sera were measured, results were 
summed up (two-columns, left) and are presented along with the calculated concentration (grey column, 
right) (left). The recovery of 3-T1AM spiked into serum in rising concentrations (right). 
The stability of 3-T1AM was also tested in serum. 3-T1AM was stable at RT and 4°C overnight 
(83% and 93%, respectively) as well as after four freeze-thaw-cycles [98%] (Figure 33). 
 
 
Figure 33: Stability of 3-T1AM in human serum. 
Stability of 3-T1AM in serum stored at RT or 4°C overnight and after 4 freeze/thaw cycles. 
 
In healthy human serum, 3-T1AM was reliably detected and quantified in the nM concentration 
range by the CLIA. Human plasma and serum are widely used matrices in clinical and biological 
studies. However, different collecting procedures and the coagulation cascade influence concen-
trations of proteins and metabolites in these matrices (Yu, et al., 2011). Therefore, the 3-T1AM 
concentrations in EDTA plasma and serum samples collected simultaneously from ten individu-
als were analyzed. No statistical difference, but a slight trend towards lower 3-T1AM levels in 
plasma was observed (Figure 34).  
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Figure 34: 3-T1AM concentration of sera and plasma of 10 healthy individuals.  
There was no statistical difference (unpaired t-test). 
 
3.2.5 3-T1AM binding studies 
Agents, like 8-anilino-1-naphtalene sulfonic acid and sodium salicylate, which interfere with the 
TH binding proteins are often used for total TH measurements. Sodium salicylate was shown to 
interfere with T3 and T4 binding to TBG (Christensen, 1959; Larsen, 1972). In contrast to TH, a 
high fraction of 3-T1AM (> 90%) is specifically bound to apoB100, but not to the classical TH 
binding proteins. Therefore, the influence of binding proteins to 3-T1AM concentrations was stud-
ied analysing the role of free vs. total 3-T1AM. In the first description of serum analysis from De-
Barbar, et al. (DeBarber, et al., 2008), 8 M urea at 80°C for 30 min was used to dissociate 3-
T1AM from its binding protein (Figure 35 left). Addition of 8 M urea to Lyphocheck, a commer-
cially available human standard serum, increases 3-T1AM concentration, but as illustrated with 
NaCl as reference material, urea itself increase 3-T1AM in the CLIA to the same extent as in 
Lyphocheck.  
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Figure 35: 3-T1AM binding studies. 
3-T1AM binding studies using 8 M urea as agent interfere with binding proteins (left). NaCl served as 
negative control and diluting agent (n=2, measurement in duplicate). 3-T1AM serum concentration in five 
patients before and after lipoprotein apheresis (right). 
 
The therapy of lipoprotein apheresis is used for patients with hereditary familial hypercholester-
olemia showing additional risk factors for cardiovascular diseases (Thompson, 2010). Since 
lipoprotein apheresis is being performed with increasing frequency and 3-T1AM binds tightly to 
apoB100, 3-T1AM concentration before and after lipoprotein apheresis in 5 patients was investi-
gated. Before lipoprotein apheresis the mean 3-T1AM serum concentration was 111 ± 40 nM 
and significantly decreased to 48 ± 14 nM after therapy (Figure 35 right). 
 
3.2.6 3-T1AM is mainly produced extrathyroidally 
The median serum concentration of 3-T1AM in 13 adult healthy subjects was 66 ± 26 nM and 
therefore comparable with previous LC-MS/MS results (Geraci, 2008) and in the same nM con-
centration range as the thyroid pro-hormone T4. In sera of 105 thyroid cancer patients on TSH 
suppressive L-T4 therapy 3-T1AM levels were significantly higher than in controls (Figure 36). 
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Figure 36: 3-T1AM levels in 13 healthy individuals and 105 thyroid cancer patients.  
Median values are indicated by horizontal lines. There was a significant difference in median values be-
tween the two groups (unpaired t-test, (*** p<0,001)). 
 
 
However, there was no significant correlation between 3-T1AM levels and TSH (Figure 37 left) or 
fT4 (Figure 37 right), respectively, in the thyroid cancer cohort. In the whole group of thyroid can-
cer patients 3-T1AM was age-independent, but a trend towards slightly higher levels in sera of 
females (125 nM, n=80) than in those of males (110 nM , n=25) was observed while not reach-
ing statistical significance (Figure 38).  
 
 
Figure 37: Correlation of 3-T1AM and TSH (left) in the thyroid cancer cohort.  
There was no correlation or statistical significance. 
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Figure 38: Correlation of 3-T1AM and age (male patients left, female patients middle) and sex (right) 
in the thyroid cancer cohort.  
There was no correlation or statistical significance. 
 
3-T1AM was also detected in 10 T4-substituted patients with pituitary insufficiency. While fT4 
[18.1 vs. 11.4 nM] and fT3 [4.9 vs. 3.7 nM; p< 0.001 in both] significantly decreased during T4 
withdrawal after 6 days in these patients, 3-T1AM levels remained constant [97 vs. 92 nM], sug-
gesting differences in homeostatic regulation between these TH metabolites (Figure 39). 
 
Figure 39: Exploratory study of 10 T4-substituted patients with pituitary insufficiency before and 
after 6 days of L-T4 withdrawal. 
Serum concentrations of 3-T1AM (left). fT4 (middle) and fT3 (right) in this cohort. Statistical significance 
was calculated using paired t-test (*** p<0,001). 
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3.2.7 3-T1AM levels in murine serum 
Since the established human 3-T1AM assay was developed with a goat-anti-mouse Ab as catch-
ing Ab, the coating protocol was modified for the measurement of murine serum. To reliable 
measure murine 3-T1AM, the MAb 9C5 was directly coated onto the plate (Figure 40).  
 
Figure 40: 3-T1AM standard curves of four different coated plates using different MAb concentra-
tions (left) and four different mouse serum with 40 ng/well coated plates (right). 
Different MAb concentrations were tested using 3-T1AM standard curves diluted in 7%-BSA-
PBST (Figure 40 left). Finally, 40 ng/well MAb was chosen to measure 3-T1AM in different 
mouse sera (Figure 40 right). In one mouse serum (number 3), no 3-T1AM could be detected 
creating a 3-T1AM deficient serum for the generation of standard curves. However, in all other 
sera 3-T1AM levels ranged from 23 to 150 nM.  
 
3.3 The role of the AADC in thyronamine biosynthesis 
TAM exhibit great structural similarity to TH, and biosynthesis from TH appears likely. The bio-
synthetic pathway would require decarboxylation and one or more deiodination steps to convert 
e.g. T4 into a 3-T1AM. It was shown previously that TAM are substrates for DIO and several pos-
sible pathways were suggested, but the decarboxylating enzyme which was postulated re-
mained elusive. The PLP-dependent enzyme AADC has been suggested several times as the 
TH decarboxylating enzyme (Braulke, et al., 2008; Doyle, et al., 2007; Scanlan, et al., 2004). 
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3.3.1 Verification of AADC enzymatic activity using L-DOPA 
To test the hypothesis that AADC converts TH into TAM, decarboxylation of L-DOPA to do-
pamine served as a positive control. Using the QTRAP®4000 LC-MS/MS, the detection of L-
DOPA and dopamine as well as almost all added TH and TAM standards was possible. This 
enabled us to study the decarboxylation reaction. In order to confirm that the recombinant hu-
man AADC preparation was active and functioning properly, the enzyme was incubated with one 
of its known substrates, L-DOPA.  
Figure 41: The decarboxylation of L-DOPA to dopamine by AADC as positive control.  
LC-MS/MS detection (two transitions per compound) of standard solutions of L-DOPA and dopamine. (A). 
QTRAP®4000 LC-MS/MS detection (two transitions) of dopamine after incubation of AADC with 1 "M L-
DOPA (conditions: 20 min, 37°C, pH 6.8; n=3) (B). The decarboxylation of 1 "M L-DOPA to dopamine by 
AADC is inhibited by heat and carbidopa (n=3) (C) and concentration-dependent (conditions: 30 min, 
37°C, pH 6.8; n=3) (D). Data show the area under the curve (AUC) in counts per second (cps). 
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Figure 41A shows the chromatographic separation of a standard solution of L-DOPA and do-
pamine. In Figure 41B the result of the 30 min incubation of L-DOPA with the AADC is shown. 
Incubated L-DOPA was quantitatively converted into dopamine. The decarboxylation to do-
pamine was inhibited both by heat-inactivation and by the specific AADC inhibitor Carbidopa 
(Figure 41C). Under the reaction conditions chosen, dopamine formation increased in a concen-
tration-dependent manner (Figure 41D). These results show that the AADC preparation used for 
all experiments was enzymatically active on its proper substrate L-DOPA.  
3.3.2 AADC does not decarboxylate thyroid hormones 
In order to test whether the active AADC preparation also decarboxylates TH, the experiment 
from Figure 41B was repeated under standard incubation conditions but with TH as substrates. 
 
Figure 42: AADC does not catalyse the conversion of rT3 to rT3AM.  
QTRAP®4000 LC-MS/MS analysis (two transitions per compound) of T3, rT3, T3AM and rT3AM standard 
solutions (A). LC-MS/MS analysis two transitions) of the incubation of 100 nM rT3 with active AADC (con-
ditions: 30 min, 37°C, pH 6.8, n=3) (B). 
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Figure 42A shows the chromatographic separation of a standard solution of T3, rT3, T3AM and 
rT3AM. Figure 42B shows a representative result of the incubation (30 min) of 100 nM rT3 with 
active AADC. There was no conversion of rT3 to rT3AM. This experiment was performed with all 
other eight possible TH (T4, T3, 3,5-T2, 3,3’-T2, 3’,5’-T2, 3-T1, 3’-T1, T0) without detecting any TAM 
formation (not shown). Higher concentrations of TH (up to 5 "M) were also assayed to rule out 
the possibility of weak binding due to a high Km, but no TAM formation was observed. To check 
further if the possible precursor of TAM is 3-T1 or 3,5-T2 instead of rT3, we repeated this experi-
ment and also increased the incubation time up to 3 h. Neither a 3-T1AM (Figure 43A) nor a 3,5-
T2AM (Figure 43B) peak was detected but the substrates 3-T1 and 3,5-T2 were still found in the 
incubated sample. 
 
Figure 43: Incubation of 3-T1 and 3,5-T2 as potential precursors of TAM.  
LC-MS/MS analysis of the incubation of 3-T1 (A) and 3,5-T2 (B) with AADC (conditions: 37°C, pH 6.8, 
30 min and 3 h, respectively). Heat-inactivated AADC served as negative control. 
 
3.3.3 Influence of incubation temperature, time and pH on AADC activity 
Incubation conditions, namely pH (Figure 44A), temperature (Figure 44B), and reaction time 
(Figure 44C), were varied to test whether this might enable the decarboxylation of rT3 to rT3AM. 
Figure 44A-C show the area under the curve of rT3 and rT3AM at different pH levels, tempera-
tures and time-points. However, rT3AM was not detected in any of the samples, showing that 
AADC cannot catalyze the decarboxylation of rT3 to rT3AM.  
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Figure 44: Influence of pH, temperature and time on the incubation of rT3 with AADC.  
QTRAP®4000 LC-MS/MS analysis of the incubation of rT3 with AADC. Influence of pH: conditions: 30 
min, 37°C, pH 5.0-8.8, n=3 (A). Influence of temperature: conditions: 30 min, 34.6°C - 43.0°C, pH 6.8, n=3 
(B). Influence of time: conditions: 1 min-18 h, 37°C, pH 6.8, n=3 (C). 
 
3.3.4 3-T1AM concentration in patients with AADC deficiency 
If AADC was involved in TAM biosynthesis, one would expect lower levels in patients deficient in 
AADC. 3-T1AM concentrations in plasma samples of four anonymous patients with biochemically 
confirmed AADC deficiency were measured using the newly established 3-T1AM CLIA. The 
mean plasma concentration of 3-T1AM was 46 ± 18 nM and thus comparable (unpaired Mann 
Whitney test, p= 0.2339) with healthy control (n=13, 66 ± 26 nM) (Figure 45). Consequently, this 
supports the obtained in vitro findings that AADC is not involved in TAM biosynthesis. 
 
Figure 45: 3-T1AM plasma concentrations in four patients with biochemically confirmed AADC de-
ficiency and 13 healthy controls.  
Mean values are indicated by horizontal lines. There was no statistical difference between both groups 
(unpaired Mann Whitney test, p= 0.2339). 
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4 Discussion 
TAM represent a novel class of TH-derived endogenous signalling compounds with remark-
able biological effects on core body temperature, cardiac function, energy metabolism, and 
neurotransmission (reviewed in Piehl and Hoefig, et al. (Piehl, et al., 2011)). 3-T1AM is the 
major TAM found in serum and tissue, but its physiological concentration measured with LC-
MS/MS or other methods is still under discussion. TAM are formed from their precursor TH 
via a combination of deiodination and decarboxylation in target tissues (Saba, et al., 2010). 
T4AM and its derivatives with lower iodine content are substrates of the three DIO enzymes 
(Piehl, et al., 2008). However, the putative decarboxylase proposed to generate TAM from 
their corresponding TH is still elusive.  
Hence, the aims of the thesis were the establishment of the TH and TAM analysis in different 
matrices using LC-MS/MS as well as the identification of the TH decarboxylase(s) necessary 
to generate 3-T1AM in vivo. 
 
4.1 Analytics of 3-T1AM and thyroid hormone metabolites 
One essential objective of this thesis was the analysis of all possible TH and TAM metabo-
lites in different matrices of a single sample and in one analytical LC-MS/MS run. During the 
past years, sensitive LC-MS/MS based methods were the best choice to study endocrine 
parameters like steroids, vitamin D or TH in a single sample and in different matrices 
(Adamec, et al., 2011; Surowiec, et al., 2011; Thibeault, et al., 2012; Vogeser and Parhofer, 
2007).  
LC-MS/MS is a technique that identifies the analyte by the mass-to-charge ratio of parent 
and fragmentation ions and the HPLC retention time. The quantification of analytes is mainly 
achieved by determining the ratio of analyte to isotopically labeled internal standard, a 
method called isotope dilution. LC-MS/MS assays are highly accurate and have low limits of 
detection, and most importantly they are specific for the analyte (Jonklaas, et al., 2009; 
Vogeser and Seger, 2012).  
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4.1.1 LC-MS/MS measurement of 3-T1AM and thyroid hormone metabolites 
Several LC–MS/MS methods have been developed to measure free (non-protein bound) and 
total (free + protein bound) TH and their metabolites in human serum or plasma (Gu, et al., 
2007; Kunisue, et al., 2010; Lembcke, et al., 2005; Soldin and Soldin, 2011; Soldin, et al., 
2005; Yue, et al., 2008). The diagnostic accuracy of total TH measurements would only be 
proportional to that of free TH if all individuals would have similar binding protein concentra-
tions. In consensus with the free hormone hypothesis, only the free fraction of TH is respon-
sible for biologic effects (Bartalena, et al., 1996; Ekins, 1992; Mendel, et al., 1988). Hence, 
the measurement of free TH concentrations in serum has been accepted to be clinically use-
ful and the more physiological parameter, especially in case of serum binding-protein abnor-
malities like pregnancy (Bartalena, et al., 1996; Bhatkar, et al., 2004; Kahric-Janicic, et al., 
2007).  
In 2004, Scanlan, et al. presented for the first time the detection of 3-T1AM and T0AM in ro-
dent serum and tissues using LC-MS/MS. It was astonishing that the extraction and detection 
of 3-T1AM mainly in serum would be so challenging. Especially the identification of its high 
affinity serum binding protein apoB100 highlights the analytical differences between TH and 
TAM (Roy, et al., 2012). While TH and TAM are highly similar in terms of structure, they pre-
fer different serum binding and transport proteins, in serum, plasma or blood and also recep-
tors. This discrepancy is also underlined by the fact that procedures employed to generate 
commercially processed TH deficient sera of different companies do not automatically elimi-
nate 3-T1AM as shown in this project (Figure 30). Although the detection of free and total TH 
in serum using LC-MS/MS is increasingly used in research and even in clinical laboratory 
medicine, controversies still exist about the physiological 3-T1AM serum concentration using 
LC-MS/MS (Ackermans, et al., 2010; Saba, et al., 2010; Soldin, 2009). All attempts so far to 
extract endogenous 3-T1AM from human serum and to efficiently and quantitatively recover 
3-T1AM using LC-MS/MS gave inconsistent results. Reproducible protocols may only provide 
the free or at least a fraction of non-apoB100 bound 3-T1AM. Using the API®5500 LC-
MS/MS as the currently most sensitive LC-MS/MS on the market, Soldin, et al. published a 
LC-MS/MS method for the detection of free 3-T1AM in serum (Soldin, 2009).  
Concerning human serum, the focus in this project was on the determination of TAM (T0AM, 
3-T1AM) and TH metabolites (T4, T3, rT3, 3,5-T2). In cooperation with Prof. Dr. Daniel (Mo-
lecular Nutrition Unit, TU Munich), the parallel measurement of human serum samples with 
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the QTRAP®5500 LC-MS/MS and with our QTRAP®4000 (both from AB SCIEX) was done. 
Whereas the QTRAP®4000 only detects T4 and T3 in serum, the more sensitive 
QTRAP®5500 additionally detects the TH metabolites rT3 and 3,5-T2 above the LOQ with 
safe signal intensities over noise. However, endogenous 3-T1AM was still not detected using 
this sensitive LC-MS/MS system suggesting good SPE extraction efficiencies for TH but not 
for TAM. Access to a QTRAP®5500 LC-MS/MS would provide the opportunity to test differ-
ent SPE and LLE methods for the reproducible detection of 3-T1AM. The ambitious goal to 
measure all TH and TAM in one sample was not yet achieved in serum as a suggested ma-
trix during this project. Especially in case of serum analytics, the chemistry and biochemical 
properties (e.g. serum binding proteins) of TH and TAM differ too much to extract both sub-
stance classes by one common extraction procedure. 
 
4.1.2 Detection of endogenous 3-T1AM and TH metabolites in tissue samples 
Several publications using LC-MS/MS or immunological methods already reported tissue TH 
concentrations in the pmol/g concentration range (Ackermans, et al., 2012; Kunisue, et al., 
2010; Obregon, et al., 1981; Saba, et al., 2010). In contrast, to the difficulties of TAM detec-
tion using serum, excellent measurement of 3-T1AM is obtained in samples from in vitro stud-
ies, cell culture homogenates and tissue extraction samples. In these matrices, 3-T1AM is not 
bound to serum apoB100 which is complicating the extraction procedure.  
Geraci, et al. found high (pmol/g wet weight) 3-T1AM tissue concentrations in normal human 
thyroid tissues, suggesting 3-T1AM may be synthesized by the thyroid gland, and in tissues 
previously shown to be affected by exogenous 3-T1AM administration or accumulating 3-
T1AM such as skeletal muscle and adipose tissues (Geraci, 2008). Saba, et al. observed that 
the endogenous 3-T1AM was higher in each analyzed rat organ (i.e. liver, kidney, muscle, 
heart, lung, and brain) than in rat blood suggesting a tissue specific production and/or accu-
mulation of 3-T1AM (Saba, et al., 2010). However, the difference between “high” tissue and 
“low” serum levels of 3-T1AM (Saba, et al., 2010) could be due to extraction problems of 3-
T1AM in serum. It is not mentioned, if the samples were of euthyroid rats and if the animals 
were perfused in order to remove or minimize residual blood containing TH bound by serum 
transport proteins TBG, TTR and albumin. Nevertheless, it seems that 3-T1AM acts like a 
real endocrine hormone which is secreted by a cell or a gland directly into the bloodstream.  
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In many of the analysed perfused mouse organs in this project, T4, T3, rT3, 3,5-T2, and 3-
T1AM were detectable suggesting a wide tissue distribution of endogenous 3-T1AM. In 
mouse thyroids, 3-T1AM was measured in the same concentration range (pmol/g wet weight) 
as T4 and T3. Up to now, it is not clear if 3-T1AM is only taken up from the blood by the highly 
vascularized thyroid or if 3-T1AM is produced from TH within the thyroid tissue. However, 
endogenous 3-T1AM thyroid content is still higher compared to other tissues. Studying the 
effect of Tg proteolysis and decarboxylase inhibitors on thyroidal TH and TAM concentration 
as well as mouse thyroids with different genetic TH axis modifications will help to understand 
the physiological role of 3-T1AM in the thyroid and to understand the possible 3-T1AM-based 
regulation of TH biosynthesis. 
The uptake of exogenous radiolabeled 3-T1AM from the blood stream revealed that 3-T1AM 
is taken up by all tested organs (Chiellini, et al., 2012). A significant increase in tissue vs. 
blood concentration occurred in gallbladder, stomach, intestine, liver and kidney reflecting a 
biliary excretion and enterohepatic recycling of 3-T1AM. These radiotracer studies reveal that 
liver, muscle and adipose tissues should be regarded as 3-T1AM storage sites. 
 
 
Figure 46: Tissue distribution, biliary excretion and enteric reabsorption of 3-T1AM. 
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4.1.3 Cellular uptake of 3-T1AM and T3 in FRTL-5 cells 
The known molecular targets of 3-T1AM include both intracellular (e.g. DIO, Sulfotransferase, 
MAO) and plasma membrane proteins (e.g. TAAR1), suggesting that cellular transport of 3-
T1AM may be important for its biological action (Ianculescu, et al., 2009). Other structurally 
related compounds, including TH and biogenic amines are translocated across plasma 
membranes by various cellular transporters (Kristensen, et al., 2011; Visser, et al., 2011). 3-
T1AM has recently been found to be transported into a variety of cell types via a specific 
transport mechanism which can be saturated and inhibited (Ianculescu, et al., 2009). No sin-
gle specific TAM transporter has been identified up to now; however, the sodium and chlor-
ide independent, pH dependent, TAM specific intracellular transport may involve multiple 
transporters (Ianculescu, et al., 2009). 3-T1AM is not transported into the cell via TH trans-
porters (Ianculescu, et al., 2010; Ianculescu, et al., 2009; Kinne, et al., 2010; Scanlan, et al., 
2004). 3-T1AM itself inhibits TH transporters like MCT8 or MCT10 (Ianculescu, et al., 2010). 
The time-dependent uptake of 3-T1AM and T3 by the differentiated thyroid follicular cell line 
FRTL-5 which is derived from normal rat thyroid could be demonstrated in this work. In par-
ticular in case of T3, its successful uptake into the cell is a prerequisite for biological action, 
since the THR is localized in the nucleus. T3 can be transported into the cells by TH trans-
porters like MCT8 expressed in FRTL-5 cells. Due to the localization of the 3-T1AM receptor 
TAAR1 or other potential GPCR targets in the cell membrane, its transport into the cells is 
not essential for the induction of biological effects. However, 3-T1AM uptake into the cells 
would increase the number of feasible signaling pathways. The cellular FRTL-5 uptake of 3-
T1AM and TAAR1 expression in FRTL-5 cells and human thyroid tissue was independently 
shown by Agretti, et al. (Agretti, et al., 2011). FRTL-5 cells are able to take up, accumulate, 
deiodinate and oxidatively deaminate exogenous 3-T1AM providing evidence for uptake into 
the cell (Agretti, et al., 2011).  
Roy, et al. postulated that 3-T1AM can be taken up via the LDL-receptor (Roy, et al., 2012). 
The LDL-receptor is a cell surface receptor that mediates the uptake of LDL particles from 
the bloodstream via receptor-mediated endocytosis (Hobbs, et al., 1990). FRTL-5 cells pos-
sess high affinity LDL receptors which bind, internalize, and degrade LDL (Bifulco, et al., 
1990). Hence, the cellular uptake of 3-T1AM into FRTL-5 cells via endocytosis is also feasible 
but not proven until now. 
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4.1.4 Immunoassays to measure thyroid hormones and their metabolites 
Currently, serum-based immunoassays are available for measuring both total TH (T4, T3, and 
rT3) concentrations as well as the free TH (T4 and T3). However, the difficulties with immuno-
assays to measure accurately TH that circulate in low concentrations in the bloodstream are 
well-known and some are mentioned below. Especially free TH immunoassays are known to 
be susceptible to fault. Jonklaas, et al. postulated that LC-MS/MS methods are more specific 
than immunoassays for TH measurement and quantification (Jonklaas, et al., 2009). TH 
autoantibodies (THAA) disrupt the equilibrium between TH and their binding proteins. This 
may lead to false estimations of free T4 and free T3 measurements (Vyas and Wilkin, 1994). 
A multicentre comparison of free TH immunoassays showed that a large variability in meas-
ured values is still present (Giovannini, et al., 2011). Hence, the reference value for free TH 
is individual for each assay type (direct or indirect measurements). Beside the assay type, 
the free TH value is influenced by the assay temperature. A temperature study by Soldin, et 
al showed that both free T4 and free T3 concentrations are 1.5 times higher at 37°C than at 
25°C (Soldin, et al., 2005). Remarkably, several studies have shown that the binding affinity 
of TBG for TH is very sensitive to temperature variations (Ross and Benraad, 1992; van der 
Sluijs Veer, et al., 1992). Other endogenous substances like heterophilic antibodies, lipids, 
immunoglobulins, indoxyl sulphate, indole acetic acid and hippuric acid in serum may inter-
fere with TH measurements when immunoassays are used (Ghosh, et al., 2008; Iitaka, et al., 
1998; Soldin and Soldin, 2011). The blood of pregnant woman contains a lot of non-specific 
heterophilic antibodies, and these clearly affect the validity of total and free TH measure-
ments. In non-pregnant women, there is a fairly good agreement between immunological and 
LC-MS/MS methods for total T4. But during pregnancy, the correlation between immunoas-
say and LC-MS/MS results became poorer and the correlation coefficients in fact decreased 
with increased gestational age (Kahric-Janicic, et al., 2007). Effects like this need to be vali-
dated for the newly established 3-T1AM immunoassay. 
4.1.5 Detecting 3-T1AM in serum using the newly established immunoassay 
Besides the rapid development of LC-MS/MS based methods for a wide number of bio-
chemical analytes, classical MAb-based immunoassays represent the predominant tool used 
for routine analysis of endocrine parameters. At the beginning of this thesis, no poly- or 
monoclonal antibody to establish a sensitive 3-T1AM immunoassay in serum had been de-
veloped. As it has been thought to be very difficult to raise antibodies against 3-T1AM for 
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development of an immunoassay, the detection of 3-T1AM using LC-MS/MS after extraction 
with deuterated 3-T1AM was used for quantitative analysis. The development of a highly spe-
cific MAb against 3-T1AM distinguishing this metabolite from numerous other structural ana-
logs like other TAM, TH and TAc seemed to be unlikely. Most of these compounds only differ 
in the number and/ or position of an iodine atom or the deaminated/ decarboxylated side 
chain. No significant cross-reactivity or interference between 3-T1AM and the tested ana-
logues was observed. However, cross-reaction may still exist between the antibody and 
other, yet untested TH analogues like TH/TAM sulfates or glucuronides. 
There were some publications describing the generation of MAb against small molecules like 
T4 and dopamine (Chagnaud, et al., 1987; Doi, et al., 1998). On the basis of the generation 
of a MAb against T4 using EDC as a coupling reagent and BSA as a carrier protein, the 3-
T1AM-BSA hapten was formed via the amino group of the side chain of 3-T1AM. This type of 
coupling was daring because the side chain is the structural unit where TAM differ from TH 
and TAc. Using the hybridoma technique, MAb were produced to develop a highly specific 
MAb-based quantitative CLIA for quantification of 3-T1AM in human serum. The observed nM 
concentration range of endogenous 3-T1AM in human serum provide additional evidence that 
this re-discovered TH metabolite is of high physiological relevance. Gender-specific differ-
ences as observed in the thyroid cancer cohort can be due to sex-differences in apoB100 
serum levels (Matthan, et al., 2008). The major advantage of this immunoassay is the elimi-
nation of an extraction step. Thus, the higher serum levels measured with this technique in 
comparison to LC-MS/MS likely reflect more efficient capture of total serum 3-T1AM than 
methods involving treatment of serum with denaturing organic solvents which may change 
chemical 3-T1AM properties. As often observed in immunoassays, the 3-T1AM concentra-
tions differ between plasma and serum samples. However, many factors as mentioned 
above interfere with immunological methods. More studies are necessary to clarify which 
factors disturb the newly 3-T1AM assay. Nevertheless, the immunoassay retains the advan-
tages of low cost, low sample volume requirement, robustness, simplicity, high throughput, 
and adequate sensitivity. If the assay will also be applicable to measure serum of other spe-
cies remains to be seen. Clinicians are mostly interested in obtaining serum-free T4 concen-
trations for the diagnosis of thyroid disease (Soldin and Soldin, 2011). The “free hormone” 
concept is generally accepted as an appropriate measure for T4 but more clinical studies are 
required to investigate whether this will also be true for 3-T1AM in the context of the avid 
physiological binding of 3-T1AM to apoB100. 
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4.1.6 Explaining the differences of 3-T1AM levels measured with the 3-T1AM CLIA 
and LC-MS/MS methods  
Using the newly established CLIA, human 3-T1AM serum concentrations are found in the 
same nM concentration range as the thyroid pro-hormone T4, whereas most studies using 
LC-MS/MS measured 3-T1AM levels in the pM range. However, the CLIA was not the first 
method, detecting such high 3-T1AM concentrations in human serum. In 2008 Geraci, et al. 
showed at the ATA meeting 2008 in Chicago (USA) the first endogenous 3-T1AM nM con-
centrations in human tissues and serum using a SPE extraction and LC-MS/MS method.  
One reason for the analytical discrepancy between both methods might therefore be the pre-
analytical sample preparation in LC-MS/MS studies which require protein precipitation, SPE/ 
LLE or sample adsorption to the required precolumn of the LC system. Most LC-MS/MS pro-
cedures need such a step for sample concentration on the LC precolumn and/or protein/lipid 
removal before sample application, whereas the established immunoassay works with native 
serum samples requiring no pretreatment. All available LC-MS/MS methods involve an ex-
traction step for 3-T1AM and it is not known yet which extraction methods are needed to effi-
ciently extract endogenous 3-T1AM that is by all measures tightly bound to serum proteins. 
Adding synthetic 3-T1AM IS to serum and using these to gauge extraction efficiency does not 
accurately replicate the extraction efficiency of endogenous 3-T1AM.  
A high fraction of 3-T1AM might be precipitated during the sample workup. If the total 3-T1AM 
serum concentration is in the nM concentration range and the circulating apoB100 concen-
tration range from 1.5 - 3.0 µM, then the 3-T1AM serum binding sites are in excess compared 
to the total 3-T1AM serum concentration suggesting that it is largely bound- and not free- in 
circulation (Roy, et al., 2012). Additionally to the studies by Saba, et al. (Saba, et al., 2010) 
and Soldin, et al. (Soldin, 2009), the estimation of 3-T1AM in serum would indicate a free 
fraction of only 1‰ detected by LC-MS/MS while the CLIA taking advantage of a high affinity 
and avidity MAb might be able to efficiently compete with apoB100 and thus quantify total 3-
T1AM. The free fraction of 3-T1AM in serum might be as low as that of T4, which is bound to 
the high affinity binding proteins TBG and TTR in addition to albumin. All of these TH binding 
proteins prefer alanine [TH] and acetic acid [TAc] side chain derivatives but not decarboxy-
lated side chain derivatives [TAM]. Maybe the amino-group of TAM is protected by apoB100. 
This property may distinguish 3-T1AM from other biogenic amines with short half-lives in cir-
culation for which no such high affinity binding proteins have been reported.  
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In conclusion, LC-MS/MS based methods require preanalytical SPE/LLE extraction of human 
serum. This step might not (yet) be working perfectly at recovering 3-T1AM and yield results 
something closer to free non-protein/lipid-bound 3-T1AM or only a fraction of total/bound 3-
T1AM. The finding that circulating 3-T1AM is largely bound to apoB100 may explain the dis-
crepancy in the reported serum levels of 3-T1AM using different bioanalytical methods (Roy, 
et al., 2012). The CLIA might effectively compete for apoB100-bound 3-T1AM thus allowing a 
better approximation of total (including (lipo-)protein bound) 3-T1AM. For the future, determi-
nation of apoB100 in samples and correlation with 3-T1AM will help to understand the physio-
logical consequence of the 3-T1AM binding to a lipoprotein.  
The advantages and disadvantages of both methods detecting endogenous 3-T1AM in hu-
man serum are summarized in Table 15. 
Table 15: Advantages and disadvantages of two methods detecting endogenous 3-T1AM 
Parameter SPE-based LC-MS/MS 3-T1AM CLIA 
Species Independent Challenging for rodents (MAb) 
Sample volume 200-1,000 "l 25 "l 
Preanalytical sample  
preparation 
SPE serum preparation None 
Sample number Single column extraction 96-Well Plate (40 samples) 
Assay time 2 days / 40 samples & day / 40 samples 
Costs 100 '/40 samples ~ 30 ' /40 samples 
Specificity high MAb dependent 
Sensitivity high MAb dependent 
Interference factors Matrix (ion suppression 
and/or ion enhancement), 
recovery 
e.g. Free fatty acids, lipids, 
heterophilic antibodies 
Human serum concentration ~ 0.3 nM ~ 60 nM 
Free vs. total 3-T1AM Free (+ bound 3-T1AM ?) Free + bound 3-T1AM (=total) 
 
4.1.7 The serum analysis of 3-T1AM reminds on the measurement of ghrelin 
The inconsistent analysis of 3-T1AM reminds endocrinologists e.g on the measurement of 
ghrelin, an acetyled gastrointestinal peptide. Ghrelin is involved in the regulation of energy 
balance due to its effects on the stimulation of food intake and weight gain. The mature 28-
amino acid peptide is cleaved from its precursor preproghrelin and is characterized by a very 
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peculiar structural modification, since the hydroxyl group of serine in position 3 is covalently 
acylated by an n-octanoic acid residue. This chemical modification is necessary for ghrelin to 
bind to the ghrelin receptor and to exert biologic activity (Gualillo, et al., 2003). Both acety-
lated and desacetylated ghrelin forms are present in blood and both forms can be measured 
using different assays (Yoshimoto, et al., 2002). In the bloodstream, triglyceride-rich lipopro-
teins mostly transport octanoylated ghrelin whereas high-density lipoproteins and very high-
density lipoproteins transport both octanoylated and desacetylated (De Vriese, et al., 2007). 
Nevertheless, the latter form is the dominant form (~ 90%) in the circulation but the inactive 
one (Yoshimoto, et al., 2002). Since the discovery of ghrelin at the end of 1999, most studies 
describe the use of serum whereas only a few studies used plasma. Gröschl, et al. investi-
gated the preanalytical influences on the measurement of ghrelin (Groschl, et al., 2002) us-
ing a commercially available RIA. They found out, that ghrelin was stable at 4°C for up to 
three days, whereas storage at 25 °C for >1 day produced significantly lower results. Re-
peated freezing and thawing had no influence on the ghrelin concentrations while the ghrelin 
concentration is lower in citrate and lithium-heparinate plasma than in the serum samples 
(Groschl, et al., 2002). Moreover, other factors like the body weight influence the ghrelin 
measurement. Ghrelin levels in the plasma of obese individuals are lower than those in 
leaner individuals (Cummings, et al., 2002). And anorectic patients have high plasma ghrelin 
levels compared to both the constitutionally thin and normal-weight controls (Germain, et al., 
2007). Hence, the detailed description of patient samples analyzed in a study is necessary to 
classify the measured value. Furthermore, hormones like ghrelin are secreted in a circadian 
manner influencing the absolute value (Cummings, et al., 2002). Beside plasma and serum, 
several groups used already saliva to measure ghrelin levels and suggest an association of 
ghrelin level in saliva and serum (Aydin, 2007; Aydin, et al., 2005; Groschl, et al., 2005; Li, et 
al., 2011).  
 
4.2 Biosynthesis of thyronamines 
TAM are novel endogenous signalling molecules whose biosynthetic pathway is still to be 
discovered. It is important to understand the biosynthesis of this natural iodine-containing 
compound. Recent developments in the analytics of the extraordinary thyroid metabolite, 3-
T1AM, together with several TH metabolites could help to answer this question. 
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Due to their great structural similarity to TH, biosynthesis of TAM from TH is conceivable. 3-
T1AM and T0AM can theoretically be derived from TH by removal of the carboxylate group on 
the amino acid backbone in addition to deiodination, which could occur either before or after 
decarboxylation. Deiodination of various TAM by the three DIO enzymes has been demon-
strated in vitro in human cell lines (Piehl, et al., 2008). However, the TH decarboxylase, the 
sequence of reactions and locations of biosynthesis is still elusive at the moment (Wu, et al., 
2005). If 3-T1AM is produced by a combination of deiodination and decarboxylation of TH, 3-
T1AM could be one of the major end-products of TH metabolism.  
In vitro and in vivo experiments have not been able to answer the biosynthesis question until 
now. On the one hand, slow but measurable 3-T1AM production has been shown from T3 in 
rat H9c2 cardiomyocytes providing for the first time evidence of TH as TAM precursor. On 
the other hand, Ackermans, et al. e.g. could not provide evidence for TAM biosynthesis in 
vivo. They could not detect any endogenous 3-T1AM or T0AM in rat serum, human plasma or 
thyroid tissue using an online SPE extraction combined with LC-MS/MS analysis 
(Ackermans, et al., 2010). The reason for this observation could be due to an insufficient limit 
of detection and/ or preanalytical issues such as protein binding (e.g. apoB100) or rapid deg-
radation of TAM by amine oxidases (MAO and others). In addition, they treated rats for ten 
days with 13C6-T4 in different doses expecting to see the biotransformation to 13C6-T1AM. Al-
though, they detected 13C6-T4 and deiodinated 13C6-T3 in plasma and tissue samples, they did 
not determine deiodinated and decarboxylated 13C6-T1AM. Since they detected 3-T1AM and 
T0AM only after exogenous administration, they raised questions on the biosynthesis path-
ways and physiological concentrations of endogenous 3-T1AM and T0AM. However, also the 
published LC-MS/MS based serum concentrations detecting endogenous 3-T1AM still differ 
between the groups working on TAM (Table 3). 
 
4.2.1 Thyroidal biosynthesis of 3-T1AM  
In rodents, T4 accounts for approximately 50% of the TH secreted by the thyroid gland. If 3-
T1AM is a major product of T4 metabolism, a high 3-T1AM concentration might be found in 
the thyroid gland. Using the LLE-based LC-MS/MS method for the isolation of TH and TAM 
from tissues, T4, T3, rT3, 3,5-T2, and 3-T1AM were determined in perfused mouse thyroids 
suggesting thyroidal existence of 3-T1AM. These data are concordant with other publications 
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showing thyroidal 3-T1AM, but in non-perfused tissue samples (Geraci, 2008; Saba, et al., 
2010). 3-T1AM is taken up by the differentiated thyroid follicular cell line derived from normal 
rat thyroid FRTL-5 cells as shown in this work and independently by Agretti, et al. (Agretti, et 
al., 2011). Administration of 1 "M 3-T1AM for four hours results in the catabolism of 3-T1AM 
to T0AM, T1Ac and T0Ac confirming the presence of DIO and MAO activity in these thyroid 
cells. FRTL-5 cells are able to accumulate exogenous T4 and to convert it into T3 (other 
catabolites were not detected) proving that T4 is really taken up into the FRTL-5 cell. How-
ever, the complete deiodination and decarboxylation of T4 into 3-T1AM was not observed in 
FRTL-5 cells after four hours incubation of 1 "M T4 (Agretti, et al., 2011) suggesting that 
these cells might not express the desired TH decarboxylase.  
 
4.2.2 Extrathyroidal production of 3-T1AM 
Still, no evidence for TAM de novo biosynthesis in the thyroid gland from tyrosine or tyramine 
and iodination of the iodine-free T0AM has been presented as an alternative hypothesis of 
the biosynthesis pathway. However, the complex biosynthesis of diphenlyether-coupled 
(iodo-)thyronine molecules has so far only be shown in vivo in the thyroid gland, which still 
remains the major source of TH in humans and higher animals. Usually, the thyroid gland 
has been considered as the only source of TH production. In humans it is assumed, that ap-
proximately 80% of circulating T4 originates directly from the thyroid (Laurberg, 1984). Sev-
eral TH metabolites (T4, T3, rT3, 3,5-T2, and 3-T1AM) were detected in perfused mouse tis-
sues using LC-MS/MS showing extrathyroidal existence of TH metabolites and 3-T1AM. 
Nevertheless, a thyroidal production cannot be totally excluded since 3-T1AM is present in 
murine thyroids. Therefore, 3-T1AM serum levels were investigated in a thyroid cancer co-
hort. In these TSH suppressed T4-substituted patients all of whom lack functional thyroid tis-
sue after surgery and/or radioiodine therapy, 3-T1AM serum levels are detectable at equal or 
even higher levels compared to healthy controls. This underlines the theory of extrathyroidal 
3-T1AM production from exogenous T4 supplements. This assumption is supported by the 
fact that under TSH suppressive therapy, where higher than normal T4 serum values are 
reached, also 3-T1AM levels are higher than in controls. In T4 substituted thyroid cancer pa-
tients, neither age-dependent variations of serum 3-T1AM serum were observed nor did fe-
males and males show different 3-T1AM levels, which is compatible with the fact that mean 
age, body weight, and body mass index were not significantly different between women and 
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men. In addition, in T4-substituted patients with pituitary insufficiency leading to an inactive 
thyroid gland, 3-T1AM is still detected without a decrease six days after drug withdrawal, 
while fT4 and fT3 levels are already clearly diminished as expected. The 3-T1AM serum pro-
file during T4 withdrawal suggests either a rather long half-life or persisting 3-T1AM release 
into serum from intracellular TH precursors or stores. Further kinetic studies after administra-
tion of classical TH versus 3-T1AM need to be done and might also give indication on the 
source of 3-T1AM biosynthesis.  
Every now and then, the concept of extrathyroidal TH synthesis has been discussed and 
tested in several experiments of several authors providing solid evidence for the process of a 
low-level TH generation in tissues other than the thyroid gland (Cuervo Munoz, 1958; Evans, 
et al., 1966; Obregon, et al., 1981; Purves and Griesbach, 1946; Taurog and Evans, 1967). 
Nowadays, sensitive LC-MS/MS methods are used to investigate TH kinetics and metabo-
lism trying to answer the question of extrathyroidal TH formation (Nagao, et al., 2011). How-
ever, most thyroidologists are still skeptical since some experiments are only in vitro and TH 
synthesis is too unique to take place in every cell or tissue. This hypothesis of extrathyroidal 
TH synthesis is based on the observations that thyroidectomized animals still have low levels 
of TH. The reason for this might be due to TH production by extrathyroidal tissues, en-
hancement of enterohepatic recirculation and repression of TH degradation or incomplete 
removal of the thyroid gland. Taurog, et al. demonstrated in thyroidectomized rats that the 
biological actions concerning growth, metabolic rate, heart rate, and pituitary, adrenal, and 
reproductive function of iodide are attributable to the extrathyroidal formation of small quanti-
ties of T4 (Taurog and Evans, 1967). Later, they presented the existence of T4 in the plasma 
of the thyroidectomized rats that received 5 mg of iodide daily by scans of paper chroma-
tograms (Taurog and Evans, 1967). Obregon, et al. showed low levels of T4 and T3 by spe-
cific RIAs in tissues (liver, kidney, brain, heart, and hindleg muscle) from thyroidectomized 
rats that had received a single dose of 131I long after these hormones had disappeared from 
the blood circulation (Obregon, et al., 1981). However, these observations were never fol-
lowed up to clarify the source of extrathyroidal TH.  
In recent years, Meischl, et al. reported that rat H9c2 cardiomyocytes express all compo-
nents essential for TH biosynthesis. Therefore, they used spotted oligonucleotide microar-
rays to analyze the cardiac mRNA expression in normal, hypertrophic, and failing ventricular 
tissue. They found low but significant expression of Tg, NIS, pendrin, TPO, and TSHr in 
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H9c2 cells which also expressed DUOX1 and DUOX2 at the mRNA level and at the protein 
level (Meischl, et al., 2008). Moreover, Meischl, et al. showed intracrine TH production under 
their experimental conditions (Meischl, et al., 2008). They incubated H9c2 cells for 88 h in 
the presence of 50 µCi 125I/ml and subsequently induced ischemia. SDS-PAGE analysis re-
vealed that 125I was incorporated exclusively into Tg. Moreover, a low but significant pres-
ence of free T4 and free T3 were found in these cardiomyocyte lysates using a modified RIA 
(Meischl, et al., 2008). However, high iodide doses were necessary to generate TH in the 
heart which does not possess the follicular structure that is important for the TH production of 
the thyroid gland. Taken together, rat H9c2 cardiomyocytes express the main proteins ne-
cessary for TH synthesis and are able to generate low levels of TH (Meischl, et al., 2008). 
Furthermore, 3-T1AM production has been shown from T3 in these cardiomyocytes providing 
evidence of TH as TAM precursor. In these experiments, H9c2 cells were incubated for 
120 min in the presence of 1 µM 3-T1AM. The concentration of 3-T1AM in the incubation me-
dium decreased exponentially while the 3-T1AM concentration in cellular lysate increased. 
The catabolism of 3-T1AM was also investigated in cell lysates and conditioned medium 
(Saba, et al., 2010). Only 2% of TA1 was observed in the cell lysate, whereas neither T0AM 
nor TA0 was detected although these cells express DIO enzymes.  
These findings motivated our Institute to work with this cell line. However, neither the en-
dogenous expression of genes like TPO, NIS, and TSHR could be confirmed using PCR, nor 
the 3-T1AM generation from T3 as precursor. Nevertheless, Tg, as the macromolecular pre-
cursor of TH, was observed in these cells (unpublished data). Normally, Tg is thought to be 
uniquely expressed by thyroid epithelial cells. In the meanwhile, more publications appeared 
describing Tg expression in various cell types and tissues except the thyroid (Fernando, et 
al., 2012; Kaufmann, et al., 2004; Meischl, et al., 2008; Sellitti, et al., 2000).  
 
4.2.3 The human AADC is not involved in thyronamine biosynthesis 
Piehl, et al. have recently identified TAM as isoenzyme specific substrates of the DIO1, 2 and 
3 and proposed several pathways for TAM biosynthesis (Piehl, et al., 2008). Interestingly, the 
DIO isoenzyme selectivity of TAM deiodination differs from that of TH. T4AM is not a sub-
strate for DIO1 and DIO2, and cannot be deiodinated to T3AM, whereas T4AM is a substrate 
for DIO3 and is readily deiodinated to rT3AM. DIO1 and DIO2 can then sequentially deiodi-
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nate rT3AM to provide 3-T1AM. This isozyme-selective processing suggests a specific bio-
synthetic pathway for endogenous 3-T1AM production, with either T4AM or rT3AM serving as 
entry points into the pathway. These entry points would originate from decarboxylation of 
either T4 or rT3 (Piehl, et al., 2008; Scanlan, 2009), which has also been proposed as a pos-
sible precursor of 3-T1AM by the group of Dratman (Dratman, 1974; Gompf, et al., 2010).  
AADC promotes the decarboxylation of a variety of endogenous and synthetic aromatic 
amino acids (Zhu and Juorio, 1995). The functional significance of the broad substrate speci-
ficity of AADC is unknown. It has been postulated that AADC may have other functions such 
as in non-monoamine neurons, where it is also expressed (Zhu and Juorio, 1995). According 
to Dratman’s initial hypothesis presented in 1974 (Dratman, 1974), AADC has been pro-
posed several times as a candidate enzyme to convert T4, rT3 or other TH into TAM, such as 
3-T1AM and T0AM (Braulke, et al., 2008; Doyle, et al., 2007; Dratman, 1974; Klieverik, et al., 
2009; Pietsch, et al., 2007; Scanlan, 2009; Scanlan, et al., 2004; Wu, et al., 2005). Interest-
ingly, TAM were re-discovered based upon the hypothesis that analogous to the formation of 
dopamine from L-DOPA, T4 or a lower iodinated TH could be decarboxylated to various TAM 
(Cody, et al., 1984; Meyer and Hesch, 1983). Therefore, the possible role of human AADC in 
TAM biosynthesis from TH precursors was investigated as the second aim of this thesis. The 
data presented in this thesis reveal that the human recombinant AADC apparently does not 
catalyse the decarboxylation of TH under any of our experimental conditions challenging the 
initial hypothesis, while the AADC preparation actively generated dopamine from L-DOPA 
under the same conditions. In our experiments, the most important factors (temperature, 
time, pH) for enzymatic activity were varied. As reviewed by Bowsher and Henry (Bowsher 
and Henry, 1986), the rate of in vitro decarboxylation of aromatic amino acids is highly de-
pendent on the pH of the reaction medium and on the type of substrate. However, varying 
pH, incubation temperature and incubation time showed no rT3AM formation from rT3, which 
is the favoured substrate in the Dratman hypothesis (Gompf, et al., 2010). Thus, it can be 
concluded that TH are not decarboxylated by human functional AADC. These in vitro obser-
vations are further supported by the finding that 3-T1AM is detectable in plasma samples 
from patients with genetic AADC deficiency at similar concentrations as in healthy controls.  
If the decarboxylation of TH takes only place coupled to deiodination, studies using a cell/ or 
tissue homogenate rich in DIO and AADC activity would be necessary. Highest levels of tis-
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sue AADC are found in kidney, liver, and gastrointestinal tract (Bowsher and Henry, 1986), 
so that murine liver AADC could be used as an ex vivo enzyme source. 
 
Figure 47: Biosynthesis of 3-T1AM requires deiodination and decarboxylation. 
3-T1AM is structurally related to T3 since it can be produced by deiodination and decarboxylation. 
However, human recombinant AADC is not the decarboxylating enzyme. 
 
As the biosynthesis of monoamines mainly occurs in neural tissues, it is very surprising that 
AADC is highly abundant in kidney and liver where no monoamine biosynthesis is observed 
until now (Moreno, et al., 2008). Approximately 80 – 85% of T3 is generated by DIO1, pri-
marily in the liver and kidneys. Piehl, et al., tested the deiodination of every possible TH 
using murine liver homogenates as a DIO1 source as a positive control of the LC-MS/MS 
based DIO assay (Piehl, et al., 2008). The formation of 3-T1AM or other TAM from murine 
liver homogenates incubated with all nine possible TH was not observed. However, TAM are 
substrates of metabolizing enzymes like SULT (Pietsch, et al., 2007), DIO (Piehl, et al., 
2008), and MAO (Wood, et al., 2009). Although the physiological role of AADC in liver is not 
clear, these results indicate that liver AADC is not responsible for the production of TAM from 
TH. Although the AADC cannot completely be excluded as the decarboxylating enzyme in 
vivo, the findings do not support the hypothesis that AADC is a potent TH decarboxylase.  
4.2.4 Searching for a new thyroid hormone decarboxylase 
Since AADC may not be the TH decarboxylating enzyme, other candidate decarboxylases 
should be tested for their potential function to decarboxylate TH. Many of the identified de-
carboxylases have not been characterized so far and are orphan enzymes. If the new candi-
date enzyme is relatively similar to AADC, amino acid exchanges from big to small in the 
active site would be desirable. Such exchanges would create a void in the active site of the 
enzyme in comparison with AADC. This bigger active site is required, because 5-hydroxy-L-
tryptophan, one of the biggest known AADC substrates, could be an exclusion size for 
AADC. TAM, exhibiting two aromatic rings, are even bigger than 5-hydroxy-L-tryptophan and, 
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consequently, need more space in the active site. A bioinformatic search for other candidate 
decarboxylases was performed in our Institute. An interesting new candidate was found 
which shows a very promising active site (Figure 48) while being highly similar to AADC. 
 
Figure 48: Bioinformatic search for a new candidate enzyme. 
Phylogenetic tree based on all decarboxylating enzymes of human origin (A). Amino acid exchange in 
the active site between human AADC and the new candidate enzyme (B). Structure of AADC. Left the 
active site of AADC with bound inhibitor carbidopa and two exchanged amino acids in comparison to 
the new enzyme and right schematic visualization of possible binding of TH (C). Visualization using 
RasMol by Dr. Schweizer (Institut für Experimentelle Endokrinologie, Charité-Berlin, Germany). 
 
This active site exhibits, in comparison to AADC, two amino acid exchanges, which create an 
additional free space. The substrate is orientated with its carboxyl group towards the catalytic 
active lysine residue, which would make decarboxylation feasible. Hence, this new candidate 
enzyme could be able to accommodate and decarboxylate TH. Further on, an expression 
profiling showed that this enzyme is mainly expressed in hypothalamus and brain, organs 
where pharmacological TAM effects play a role. Up to now, a low decarboxylation and deio-
dination rate of T3 to 3-T1AM was shown for the first time in H9C2 cardiomyocytes, these 
cells likely contain the elusive decarboxylase (Saba, et al., 2010). However, in rat FRTL-5 
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cells no TAM formation has been observed (Agretti, et al., 2011). Experiments using this and 
other cell models may provide further insight into the biosynthesis of TAM, which exhibit re-
markable effects mainly counteracting those of the active T3. 
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5 Conclusion and future perspective 
After their initial discovery in the early 1950's, TAM are now back to the focus of basic and 
clinical research. Meanwhile, two representatives of TAM, namely 3-T1AM and T0AM, have 
been detected in vivo in several species (Hoefig, et al., 2011; Saba, et al., 2010; Scanlan, et 
al., 2004). However, it is unknown if further representatives of TAM are present in vivo. Albeit 
their physiologic function remains elusive, administration of pharmacological doses of 3-
T1AM in rodent animal models elicited prompt effects, such as metabolic depression, hypo-
thermia, negative chronotropy, negative inotropy, hyperglycemia, decreased respiratory quo-
tient, ketonuria and reduction of fat mass as well as promising therapeutic potential in the 
experimental prophylaxis and treatment of stroke have already been demonstrated (reviewed 
in Piehl & Hoefig, et al. (Piehl, et al., 2011)). In terms of structure, TAM differ from TH only 
concerning the absence of the carboxylate group of the alanine side chain. However the 
physiological TAM concentration and the pathways and regulation of TAM biosynthesis are 
still under discussion. Both classical immunoassay based methods and novel LC-MS/MS 
analytics are suitable for TH quantification in body liquid and tissue samples. Nowadays, LC-
MS/MS is used in research laboratories as gold standard method in endocrine analytics. 
However, clinical routine TH evaluation is still performed by immunoassays. 
In conclusion, the present study supports the hypothesis that LC-MS/MS measurements are 
excellent to investigate several analytes in one sample in one analytical run. A novel SPE 
method followed by LC-MS/MS was established for the simultaneous detection and quantifi-
cation of TH profiles in one serum sample independent from the species. The LLE extraction 
before LC-MS/MS analysis was successful to study tissue TH and TAM levels as well as the 
uptake of TH and TAM in vitro. Nevertheless, the determination of 3-T1AM in serum using 
LC-MS/MS was not achieved in this work. Therefore, a highly specific CLIA was developed. 
This assay was used to study the biosynthesis of 3-T1AM. Since 3-T1AM levels are detect-
able in T4-substituted patients in similar levels compared to healthy controls it was concluded 
that 3-T1AM is mainly produced extrathyroidally albeit with a serum profile distinct from that 
of T4 and T3 during T4 withdrawal. It has frequently been suggested that 3-T1AM might be 
biosynthesized of TH by deiodination and decarboxylation of the alanine side chain. Piehl, et 
al. showed that TAM are substrates for all three DIO and suggested several possible path-
ways to convert T4 into 3-T1AM, but the decarboxylating enzyme which we have to postulate 
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remained elusive (Piehl, et al., 2008). The data presented in this work suggest that AADC is 
not involved in TAM biosynthesis. The goal to find the TH decarboxylase was not achieved 
but AADC, as the first candidate enzyme for TH decarboxylation, could be excluded. There-
fore, TAM are probably formed by another decarboxylase since the conversion of T3 into 3-
T1AM was shown in H9c2 cells (Saba, et al., 2010). Hence, H9c2 cells contain the needed 
DIO enzymes as well as the postulated decarboxylase to generate 3-T1AM in vitro. Cell cul-
ture experiments with H9c2 cells and decarboxylase inhibitors would be one option to eluci-
date the TH decarboxylase. The LC-MS/MS therefore provides the best method to achieve 
this goal. The introduction of advanced and highly sensitive LC-MS/MS technology into labo-
ratory practice will help to explain the TH metabolism. 
The novel 3-T1AM immunoassay constitutes an important new tool for addressing unresolved 
questions about the physiology of 3-T1AM as a potential biomarker and its role in highly 
prevalent human diseases. In the future, comparative preanalytical experiments like the 
stated discoveries of Ghrelin are necessary for optimizing analytical conditions and setting up 
a standardized 3-T1AM blood collection, blood storage, and measurement protocol. The 
comparison of different plasma matrices and factors like body weight or circadian rhythm are 
lacking for 3-T1AM and in publication it is often unclear which kind of blood plasma source 
was used. To analyze free hormones less invasive, saliva, blood spots on filter paper, and 
urine are often used as a matrix of choice. Steroids (Al-Dujaili, et al., 2012) , TH (Higashi, et 
al., 2011) and trace elements like iodine (Grimm, et al., 2011) are measured from these ma-
trices. Up to now, urinary or salivary 3-T1AM concentrations have not been published. The 
measurement of the same serum samples using our immunoassay and LC-MS/MS are nec-
essary to define the “true” total and free 3-T1AM concentration. As mentioned above, it is 
important to keep in mind that immunological and LC-MS/MS methods might not correlate 
under some clinical conditions. Hence, more clinical studies and experiments are necessary 
to understand the physiological role and biosynthesis of TAM.  
To better understand TAM metabolism, the introduction of the measurement of TH and TAM 
conjugates like sulfates and glucuronides using the LC-MS/MS would be helpful. One 
mechanism for termination of TH and TAM action other than glucuronidation or monoamine 
oxidation is through sulfation by cytosolic SULT (Pietsch, et al., 2007). Other TAM modifica-
tions are conceivable but not published at the moment (see Figure 4).  
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TRH TSH releasing hormone 
TRHR TSH releasing hormone receptor 
TSH Thyrotropin, thyroid-stimulating hormone 
TSHR Thyrotropin receptor 
TTR Transthyrretin 
VLDL Very low-density lipoprotein 
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